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Abstract 
Apurinic/apyrimidinic endonuclease 1 (APEl) is a well-known DNA repair enzyme with 
multiple functions which include redox-activation, 3'-DNA phosphodiesterase, 3'-5' DNA 
exonuclease, and RNase H activities. Recently the novel function of APEl in RNA metabolism 
has been demonstrated. APEl was shown to possess the ability to cleaving single-stranded RNA 
as well as abasic RNA. It was also shown to physically interact with proteins involved in RNA 
metabolism. 
Previous studies have discovered the altered distribution and expression of APEl in 
different cell types including cancer cells. The cytoplasmic distribution of APEl has been shown 
to have correlation with aggressive carcinomas and poor prognoses for patients. This has led to 
an increasing number of studies on the undefined extra-nuclear roles of APEl and APEl's 
potential implications in cancer development. In this thesis, I aimed (i) to confirm the importance 
of nuclear localization signal (NLS) of APEl at the N-terminus, (ii) to discover the role of single 
nucleotide change of APEl human population variants in its sub-cellular distribution, (iii) to 
assess the cellular localization of APEl with processing bodies and stress granules under cellular 
stresses, and (iv) to initiate immuno-fluorescence analysis of APEl in breast cancer tissue. Our 
results revealed that APEl indeed has an important NLS of 1-20 amino acids at the N-terminus 
and APEl human population variants showed nuclear localizations identical to the wild-type 
APEl. There was no co-localization of APEl with PBs and/or SGs implying that APEl is 
unlikely to be involved in mRNA processing that is carried out in PBs and SGs. We observed re­
distribution of the ND20-APE1-GFP upon cellular stresses in HepG2 cells and this phenomenon 
has highlighted possible degradation of the cytoplasmic APEl upon cellular stress. This finding 
is also consistent with previous discovery of the five critical lysine residues that are responsible 
for ubiquitination and APEl degradation upon cellular stress. 
In summary, this thesis confirmed the role of the NLS in APEl cellular localization. This 
is the first study to reveal the cellular localization of human population variants of APEl and the 
N-terminal deletion variants of APEl human population variants. This research has discovered 
degradation of the cytoplasmic APEl upon cellular stress via, possibly, ubiquitination of the five 
lysine residues at the N-terminus region of 21-40 amino acids. 
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Chapter 1 
Introduction 
The mechanism of mRNA stability or turnover in cells is one of the critical points in the 
regulation of gene expression. Until recently, two exonucleolytic mRNA degradation pathways, 
including 5'- 3' and 3'- 5' exonucleolytic degradations, were considered as primary pathways. In 
contrast, the discovery of endoribonucleases that cleave mRNA molecules internally has 
enlightened an alternative mRNA turnover mechanism. Among these newly discovered 
endoribonucleases, an enzyme known as apurinic/apyrimidinic DNA endonuclease 1 (APEl) has 
recently been discovered to possess an endoribonuclease activity against c-myc messenger RNA 
(mRNA) in vitro and also possibly in vivo (Barnes et al. 2009). The objective of this Master 
thesis was to determine the cellular localization of APEl and the potential changes in its 
endoribonuclease activity in relation to its sub-cellular localization. 
This thesis concerns identifying the cellular localization of an endoribonuclease. Hence, I 
will first review mRNA degradation and its importance in gene expression. This is followed by 
discussion on different mammalian mRNA degradation pathways. The biochemical functions of 
APEl including its discovery as an endoribonuclease and its role in RNA metabolism will also 
be highlighted. Finally, localization of APEl in different cell types including cancers will be 
discussed. 
1.1 mRNA degradation and gene expression 
mRNA stability or turn-over is an integral control point in the regulation of gene 
expression in virtually all eukaryotic species. The stability of various mRNAs within a cell can 
differ and this results in a magnitude of difference in mRNA abundance following transcriptional 
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repression or transcriptional induction (Ross 1995). Earlier studies in the field have focused on 
the significance of mRNA sequences in conferring the instability to a transcript. The most 
common instability elements are found within the 3' untranslated regions (UTRs) such as in AU-
rich elements, and within coding regions of exemplary mRNAs like those of c-myc and c-fos 
(Jing et al 2005). Among factors that control RNA metabolism, dynamic association of mRNAs 
with RNA-binding proteins is known to influence the fate of mRNAs (Giorgi and Moore, 2007). 
Moreover, the stability of individual mRNAs can be controlled in response to a variety of 
stimuli, from hormones to viruses to ions, allowing for rapid changes in gene expression (Wilusz 
and Wilusz 2004). Accordingly, degradation and stability of mRNAs have been reviewed to be 
critical in the physiological and pathological processes (Bettegowda and Smith 2007). In an 
effort to understand the role of mRNA degradation in these processes, mRNA decay pathways 
and some of the responsible enzymes have been discovered. 
1.1.1 mRNA surveillance control pathways 
Cells have specific mechanisms to eliminate RNAs that are incorrectly processed or have 
improper function either because of mutations within the genes that encode them or because of 
mistakes made during their metabolism (Isken and Maquat 2007). This mRNA surveillance 
control is one of the mRNA decay pathways and mainly responsible for degrading defective or 
aberrant mRNAs resulting in proper protein synthesis (Garneau et al. 2007). The surveillance 
machineries can detect and destroy aberrant mRNAs through four different ways including non­
sense-mediated mRNA decay (NMD), Staufen-1-mediated mRNA decay (SMD), nonstop decay 
(NSD), and no-go decay (NGD). 
NMD is most well-studied mRNA surveillance pathway, which is responsible for 
degrading translationally abnormal RNAs that can cause premature termination of translation 
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(Nicholson et al. 2010). For example, random nonsense and frame-shift mutations, programmed 
DNA arrangements, or errors in mRNA splicing can all result in premature termination of 
translation and production of truncated proteins (Isken and Maquat 2007). These products have 
potential to acquire dominant-negative or gain-of-function activities as well as have no function; 
therefore, the abnormal RNAs need to be dealt with by a surveillance system. Interestingly, 
NMD is also known to reduce non-functional transcripts that have assimilated transposons or 
retroviral sequences, and target upstream open translational reading frame or an intron within 
their 3'-UTR (Mendell et al. 2004 and Wittmann et al. 2006). 
The mechanism of NMD decay is the following: cap-binding proteins (CPB), such as 
CBP80-CBP20 that bind to the 5' caps of newly synthesized transcripts before pre-mRNA 
splicing, and post-splicing exon junction complex (EJC) recruit various NMD factors such as 
Upfl, Upf2, Upf3, SMG1, eRFl, and eRF3 (Conti and Izaurralde 2005). This process will 
degrade target defective mRNAs by blocking ribosome formation and recruiting mRNA 
decaying factors. In contrast, the competitive decay pathway of NMD named SMD targets both 
CBP80-CBP20 bound and eIF4E-bound mRNAs that contains STAU1 -binding site and occurs 
independently of splicing (Kim et al. 2005). Unlike NMD, SMD down-regulates the expression 
of genes encoding mRNAs that contain an STAUl-binding site in their 3'-UTRs. 
Another mRNA surveillance pathway is NSD, which targets non-stop mRNA that lacks 
in-frame termination codons possibly due to a premature polyadenylation, an abortion of 
transcription, or an incomplete 3'-to-5' decay of ribosome-associated mRNAs (Akimitsu 2008). 
NSD in cells functions to degrade translationally dead-end templates, and to release the 
unproductively stalled ribosomes for the translation of other mRNAs (Van Hook et al. 2002 and 
Frischmeyer et al. 2002). This stalled ribosome is responsible for recruiting decapping enzymes, 
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Dcpl and Dcp2, and exosome-associated factor, Ski7, which then recruits 5'-3' exoribonuclease, 
Xrnl, and exosome to degrade target mRNA (Van Hook et al. 2002 and Frischmeyer et al. 
2002). 
The last mRNA surveillance pathway known is NGD, which targets translationally active 
mRNAs that block ribosome progression by forming stem-loop structures. NGD requires the 
recruitment and interaction of Dom34 and HBS1 to recognize stalled ribosomes, and to recruit 
the endoribonuclease for mRNA destruction (Doma and Parker 2006). Two cleavage products 
generated by the endoribonuclease are then degraded by the exosome and Xrnl (Doma and 
Parker 2006). All these aforementioned mRNA surveillance pathways are involved with stepwise 
assembly of RNA-protein complexes, and are responsible for degradation of aberrant mRNAs. 
1.1.2 General turnover by 5'-3' and 3'-5' decay pathways 
The turnover of mRNA in higher eukaryotes is a highly regulated process that plays an 
important role in gene expression. mRNA decay pathways can be generally classified into two 
broad categories - exoribonucleolytic and endoribonucleolytic pathways (Parker and Song 2004 
and Garneau et al. 2007). Primarily from studying yeast and mammals, two exoribonucleolytic 
pathways of mRNA decay, which degrade mRNA in either 5'-3' or 3'-5' directions, have been 
identified. 
In both exonucleolytic decay pathways, a variety of mRNA deadenylases, PAN2-PAN3 
(Brown et al. 1996), CCR4-NOT (Tucker et al. 2001), and PARN (Dehlin et al. 2000), usually 
initiate the degradation process by shortening the poly-A tail at the 3' end of the mRNA to a 
length of 10 to 15 nucleotides. Following this shortening of the poly A tail, mRNA is then 
subjected to degradation in either 5'-3' or 3'-5' directions. 
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In 5'-3' degradation, a decapping of the 5' end takes place by the decapping enzyme, 
Dcpl and Dcp2, with several accessory factors such as Lsm proteins (Tharun and Parker 2001), 
Edc proteins (Schwartz et al. 2003), and the DExC/H-box RNA helicase Dhhl (Coller et al. 
2001). They leave a 5' monophosphate susceptible to an exonucleolytic decay. The exposed 
transcript is subjected to cleavage by 5'-3' exoribonucleases such as Xrnlp and Ratlp in 
eukaryotic cells (Johnson 1997). In contrast, mRNAs can be subjected to degradation by 3'-5' 
decay. It is carried out by an exosome which is comprised of diverse 3'-5' exoribonucleases, 
several accessory proteins, and RNA helicases (Parker and Song 2004). 
The relative prevalence between the two exoribonucleolytic pathways remains 
controversial because it appears these two pathways redundantly supplement each other (Parker 
and Song 2004). Knocking out components of either the 5'-3' or the 3'-5' pathway had minimal 
effects on the pool of mRNAs present in yeast (Houalla et al. 2006). In mammalian cells, decay 
intermediate analysis showed that both 5'-3' and 3'-5' pathways are involved in mRNAs that 
carry adenosine-uridine rich element (ARE) suggesting dynamic and flexible pathways of 
mRNA decay (Garneau et al. 2007). 
1.1.3 Endoribonuclease decay pathways 
In contrast to exoribonucleolytic pathway and mRNA surveillance pathway, 
endoribonucleolytic cleavage of cellular mRNAs is not well-established. This may be the most 
efficient means of destroying an mRNA because it produces two fragments of mRNA that are 
susceptible to exonucleases. Some of cellular endonucleasese that have been characterized in 
recent years are PMR1, IRE1, RNase L, Dicer, Ago2, hDIS3, and APE1 (Li et al. 2010 and 
Tomecki et al. 2010). 
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PMR1 was first identified as a polysome-associated endonuclease that could destabilize 
certain serum protein mRNAs including albumin and vitellogenin (Cunningham et al. 2001 and 
Yang and Schoenberg 2004). IRE1 is known to target actively translating mRNAs that are 
usually targeted to the endoplasmic reticulum (ER) (Hollien and Weissman 2006). Then it works 
as a part of the unfolded-protein response during periods of ER stress by splicing and activating 
X-box-binding protein 1 (XBP1) gene (Calfon et al. 2002 and Lin et al. 2007) and degrading 
mRNAs that are localized to the ER (Hollien and Weissman 2006). In contrast, RNase L is 
involved in an antiviral response (Bisbal et al. 2007). Dicer and Ago2 are involved in the 
biogenesis of small RNAs, including siRNAs and miRNAs for post-transcriptional gene 
silencing (Kim et al. 2009a and Liu et al. 2004). Dicer is responsible for cleaving double-
stranded RNAs in which its product gets loaded onto the RISC complex and processed by Ago2; 
thus, they play an important role in gene regulation via RNA interference mechanism 
(Murchison et al. 2007 and Liu et al. 2004). Lastly, APE1 was recently discovered to have an 
endoribonucleolytic activitiy against c-myc mRNA in vitro (Kim et al. 2009). 
Endoribonucleases are highly specific and/or regulated and they appear to be only 
activated when needed (Garneau et al. 2007). So far, there are still many questions that need to 
be answered for a better understanding of their mechanisms and cellular functions. 
1.1.4 mRNA degradation locales 
Lastly, mRNA degradation locales such as P bodies (PBs) and stress granules (SGs) are 
additional determinants of mRNA degradation. 
Processing bodies (PBs) are granular cytoplasmic foci that have concentrated components 
of the 5'-3' mRNA-decay pathway. These components include general mRNA decay factors, 
NMD factors, AU-rich element-mediated mRNA decay (AMD) factors, and miRNA-induced 
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mRNA factors (Anderson and Kedersha 2006, Eulalio et al. 2006, Garneau et al. 2007, and 
Kulkarni et al. 2010). They are tightly linked to the decay of many short-lived mRNAs that 
contain a premature termination codon (Kulkarni et al. 2010) and ARJEs in their 3' UTR (Franks 
and Lykke-Anderson 2007) They also degrade target mRNAs of miRNAs (Liu et al. 2005). They 
are thought to have an equilibrium of formation and dissociation according to the amount of 
mRNA that is subjected to silencing, translational arrest, or rapid decay (Kulkarni et al. 2010). 
Because mRNAs in PBs are also in a dynamic equilibrium with polysomes (Teixeira et al. 2005) 
and mRNA-decay intermediates can be found in PBs (Sheth and Parker 2003), researchers 
consider PBs as the site of mRNA turnover. 
In contrast, SGs are often referred to as an mRNA silencing foci. Although PBs and SGs 
share some components and can interact physically, they are known to have an independent 
regulatory system, sets of different markers, and separate functions (Kedersha and Anderson 
2009). Interestingly, SGs are formed in response to a stress-induced translational arrest and are 
more closely linked to translation and the sorting of specific mRNAs. They are formed under 
certain environmental stresses such as in heat shock, oxidative stress or energy deprivation 
(Anderson and Kedersha 2008). Under these stressors, the translation of housekeeping genes is 
arrested and un-translated mRNA accumulates in SGs (Nonhoff et al. 2007). This creates a high 
local concentration of mRNA protein complexes (mRNPs) which in turn may increase their 
reactions in SGs or decrease their reactions in the cytosol (Buchan and Parker 2009). The 
aggregation of molecules and factors may also help to protect unemployed mRNAs from 
deleterious molecules and subsequent decay. Altogether these have potentials to alter the 
translation and degradation of the mRNA but they are yet to be carefully studied (Buchan and 
Parker 2009). 
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1.2 Biochemical functions of APE1 
Human APE1 is a 35.5kDa protein and it is often referred as APEX1 or Ref-1. It is the 
mammalian ortholog of Escherichia coli Xth (Exo III) and is known as a multi-functional protein 
that plays an important role in DNA repair upon cellular stress and DNA damage and in redox 
reactions (Tell et al. 2009). In this section, the main functions of APE1 will be discussed. This 
includes 3' DNA phosphodiesterase, 3'-5' DNA exonuclease, nucleotide incision repair (NIR), 
transcriptional repressor, and RNase H activities. 
1.2.1 Established functions of APE1 in the nucleus 
1.2.1.1 Abasic DNA incision activity 
DNA damage is continuously generated under physiological conditions due to the 
intrinsic instability of nucleic acid or because of the attacks by endogenous chemical species, 
most notably reactive oxygen or nitrogen species formed during mitochondrial respiration 
(Lindahl 1993, and Lindahl and Barnes 2000). One of the most frequent forms of DNA damage 
is the apurinic/apyrimidinic (AP) site and these AP sites are the product of both spontaneous and 
damage-induced base loss (Figure 1) (Loeb and Preston 1986). AP sites are repaired through the 
DNA base excision repair (BER) pathway and APE1 plays an important role in recognizing the 
AP site and cleaving the site to generate 3'-OH termini and 5'-deoxyribose phosphate termini 
(Izumi et al. 2000). 
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Figure 1. Structures of adenine, abasic DNA and adenosine base. The AP site is product of 
DNA damage that occurs spontaneously under physiological conditions. 
Owing to its important role in the BER pathway, the active site and essential residues 
involved in the abasic DNA cleaving activity have been studied extensively (Gorman et al. 1997, 
Mol et al. 2000, and Beernink et al. 2001). The essential residues identified are Asn68, Asp70, 
Asp90, Glu96, Tyrl71, Arg 177, Asp210, Asn212, Met270, Asp283, Asp308, and His309 in 
which most of them are involved in a hydrogen bonding network. A summary of the proposed 
role of each residue in AP site catalysis is presented in Table 1. Even though the catalytic 
mechanism of abasic DNA incision activity of APE1 and the essential residues were discovered, 
there are still debatable details which did not reach a conclusion (Gorman et al. 1997, Mol et al. 
2000, and Beernink et al. 2001). Therefore, further work is required to gain a full story of the 
abasic DNA endonuclease catalytic mechanism of APE1. 
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Table 1. Summary of proposed roles of critical residues of APEl in abasic DNA incision 
activities. 
Critical 
Residues Proposed role in AP site catalysis Reference(s) 
Asn68 Forms hydrogen bonding network Gorman et al. 1997 
Asp70 Binds to the divalent metal ion in the metal binding site A Gorman et al. 1997 
Asp90 Binds to the AP site 
Co-ordinates Mg 
Barzilay et al. 1995 
Lys98 Forms a hydrogen bonds to the carboxyl group of Gorman et al. 1997 and Asp70 
Helps induced fit during the enzyme action 
Metal ion binding site (Mg2*) 
Timofeyeva et al. 2011 
Glu96 Interacts with the phosphate group Helps nucleophilic attack and stabilizes the leaving 
group 
Gorman et al. 1997 
Tyrl71 Forms hydrogen bonding network Gorman et al. 1997 and Co-ordinates Mg2+ Beernink et al. 2001 
Argl77 
Delivers a hydrogen bond to the AP site 3'-
phosphate 
Locks APEl onto abasic DNA 
Gorman ef al. 1997 and 
Beernink et al. 2001 
Asp210 
Acts as the Lewis base 
Protonates the 3'-leaving group 
Erzberger and Wilson 1999 
Asn212 Interacts with oxygen on the phosphate backbone Orients bond for incision Rothwell and Hickson 1996 
Met270 Locks APEl onto abasic DNA 
Forms a hydrogen bond with His309 
Gorman et al. 1997 and 
Beernink et al. 2001 
Asp283 Stabilizes the positive charge that develops upon 
proton abstraction. 
Coordinates metal ions 
Mundle et al. 2009 
Asp308 Stabilize the transition state 
Facilitate the dissociation of the product. 
Acts as the general base 
Erzberger and Wilson 1999 
His309 Abstracts a proton from a water molecule to 
generate the active site nucleophile 
Mundle et al. 2009 
In BER pathway, there are enzymes that directly act on DNA and other protein factors 
that are involved in recruitment of other necessary components for the pathway. For instance, it 
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requires a DNA glycosylase which cleaves a specific modified or damaged base and generates 
the AP site (Tell et al. 2009). APEl which cleaves the AP site, DNA polymerase b which 
replaces the missing nucleotide, and DNA ligase which carries out the ligation reaction are also 
required (Tell et al. 2009). On the other hand, there are proteins that recruit other BER proteins 
and increasing overall BER pathway such as XRCC1, proliferating cell nuclear antigen (PCNA), 
and poly(ADP-ribose) (Caldecott et al. 1996). Interestingly, APEl also acts as a recruitment 
protein in the BER pathway by interacting directly or indirectly with other BER enzymes such as 
glycosylases (OGG-1, MYH, MPG), DNA polymerase b, XRCC1 and FEN1 (Tell et al. 2009). 
These interactions are also known to benefit the BER pathway through activation of the recruited 
BER enzymes (Tell et al. 2009). Therefore, APEl is considered as a key component in the BER 
pathway. 
1.2.1.2 Redox activity 
In cells, maintaining the intracellular redox balance is very important for all aerobic 
organisms because they are always exposed to the reactive oxygen species (ROS) from an 
oxidative stress. Most ROS produced in cells are the by-products of respiration and ionizing 
radiation (Tell et al. 2009). Therefore, cells have developed their own system to control the 
intracellular amount of ROS by implementing antioxidant enzymatic and non-enzymatic systems 
such as glutathione, catalase, peroxidases etc. (Tell et al. 2005). APEl has been identified as a 
nuclear redox protein which activates the DNA binding activity of several transcription factors 
such as nuclear factor-kappaB (NF-kB), early growth response protein-1 (Egr-1), p53, HIF-la, 
CREB, AP-1 and paired box-containing (Pax) proteins (Xanthoudakis and Curran 1992a and 
1992b, Huang and Adamson 1993, Gaiddon et al. 1999, and Nishi et al. 2002). There are two 
components that are considered as functional domains for the APEl redox activity. They are the 
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N-terminal region between residues 35 and 127, called redox co-activator, and one cysteine 
residue, Cys65, located in the DNA-binding domain (Tell et al. 2002 and Tell et al 2009). APE1 
provides a redox-dependent mechanism for regulation of the aforementioned target transcription 
factors (Georgiadis et al. 2008). It is carried through the action of these functional domains 
which are maintained in the reduced state (Georgiadis et al. 2008). Researchers have proposed 
that a conformational change is needed for APE1 to expose the critical residue, Cys65, to confer 
its redox activity (Georgiadis et al. 2008 and Manvilla et al. 2011). S-glutathionylation of Cys99 
and subsequent conformational change to abolish abasic DNA incision activity supports this 
hypothesis (Kim et al. 201 la). 
Recently, redox chaperone activity of APE1 has been reported, suggesting that APE1 
binds to target transcription factors and carries out its redox activity by using other reducing 
molecules such as glutathione and thioredoxin rather than by APE1 itself (Ando et al. 2008 and 
Schlotterer et al. 2010). This redox-chaperone activity is thought to be mediated by direct 
interactions between APE1 and target transcription factors and it does not require high 
concentrations of APE1 as does its redox activity (Ando et al. 2008). In contrast, very recent 
study supports APE1 as a unique redox protein by itself. This study has identified three cysteine 
residues (C65, C93, and C99) as necessary and sufficient for APEl's redox activity (Luo et al. 
2011). The residues can form disulfide bonds between them and they also can form disulfide 
bonds with thioredoxin upon oxidation (Luo et al. 2011). Therefore, it still remains unknown 
exactly how APE1 carries out its essential redox activity in vivo and further work is clearly 
required. 
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1.2.2 Other functions of APE1 
Besides the two major functions discussed above, APE1 is known to have other functions which 
includes 3' DNA phosphodiesterase, 3'-5' DNA exonuclease, nucleotide incision repair (NIR), 
transcriptional repressor, and RNase H activities. 
Firstly, APE1 has 3' DNA phosphodiesterase activities that can remove 3'-blocking 
phosphate groups to produce 3'-OH (Suh et al. 1997 and Evans et al. 2000). These 3'-blocking 
groups are generated by DNA glycosylases NEIL1 and NEIL2 (Izumi et al. 2003). APE1 also 
removes deoxyribonucleoside analogs via its 3'-5' exonuclease activity because these 
deoxyribonucleoside analogs that are formed by complex glycosylases and by radiation are 
capable of blocking repair pathway (Flaherty et al. 2002). All of these activities are estimated to 
have weaker activities than its abasic incision activity by 33-fold for 3'-5' exonuclease activity to 
a 100-fold for 3' DNA phosphatase (Wilson et al. 1995) and 3' DNA phosphodiesterase activities 
(Krokan et al. 2000). 
Other than those nuclease activities of APE1, APE1 has been implicated in NIR pathway. 
It has been suggested that APE1 can cleave the sugar-phosphate backbone of a damaged 
nucleotide and produce a break with 3'-OH and 5!-phosphate (Ischenko and Saparbaev 2002). 
The 3'-OH end gets repaired with DNA polymerase that adds a new nucleotide to fill the gap and 
the 5'-phosphate end gets processed by FEN1 (Ischenko and Saparbaev 2002). The optimal 
conditions for the NIR pathway is very different than that of abasic DNA incision activity (Gros 
et al. 2004) which suggests NIR-related activities of APE1 are determined by different domains 
and different mechanisms (Gros et al. 2004). 
APE1 has also been suggested to play a role in negatively regulating the Racl/GTPase to 
prevent oxidative stress (Ozaki et al. 2002) and to regulate vascular tone and endothelial nitric 
oxide production (Jeon et al. 2004). It was first discovered in the promoter of the human 
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parathyroid hormone (PTH) gene and later in the APEl promoter itself (Okazaki et al. 1994 and 
Izumi et al. 1996). APEl is considered as a transcriptional repressor as a component of a trans­
acting complex through binding to negative calcium responsive elements (N-CaRE) (Okazaki et 
al. 1994). This is supported by another study done by Bhakat et al. (2003) which showed 
calcium-induced APEl acetylation at lysine residues 6 and 7 and this acetylated APEl has an 
increased capability of binding nCaRE elements. This APEl acetylation can turn specific 
functions of APEl on and off; therefore, it suggests the important role of specific post-
translational modifications of APEl as switches. Post-translational modifications are considered 
as important mechanisms in regulating the multiple functions of APEl and interactions of 
proteins with APEl (Bhakat et al. 2003). 
Lastly, APEl is known to possess RNase H activity (Barzilay et al. 1995) as well as RNA 
binding ability in association with ribosomes in the cytoplasm of different cell types (O'Hara et 
al. 2009). It also has the ability to interact with other protein factors involved in RNA 
metabolism such as YB-1 (Chattopadhyay et al. 2008), RNA polymerase II (Sengupta et al. 
2011) and hnRNP-L (Xanthoudakis et al. 1994). Recently, researchers have discovered the 
ability of APEl to cleave abasic ssRNA molecules (Berquist et al. 2008) and c-myc mRNA 
(Barnes et al. 2009) providing support for the notion that APEl is an ideal candidate for a novel 
RNA cleansing process. These roles of APEl in RNA metabolism will be further discussed in 
more detail in the following section. 
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1.3 APE1 in RNA metabolism 
APE1 serves multiple functions in the cell. Previously known functions include 
endonuclease activity on abasic DNA, redox activation of transcription factors implicated in 
apoptosis and cell growth, as well as 3' phosphodiesterase, 3'-5' exonuclease, and RNase H 
activities. There have been a few skeptical discoveries of association of APE1 with other factors 
that are involved in RNA metabolism and RNase H activities of APE1 in the 1990s 
(Xanthoudakis et al. 1994 and Barzilay et al. 1995). And recently there have been increasing 
studies on the novel functions of APE1 in controlling RNA metabolism. This phenomenon is 
expected because it opens up the new areas of studying multiple functions of APE1 in 
translational research. Up to date, there are three components that support this new role of APE1 
in RNA metabolism: (i) physical association of APE1 with other factors that are involved in 
RNA metabolism, (ii) discovery of abasic RNA incision activity and its role in rRNA control, 
and (iii) discovery of endoribonuclease activity of APE1 and its role in the control of mRNA 
abundance. 
1.3.1 Physical association of APE1 with proteins involved in RNA metabolism 
The first evidence of the involvement of APE1 in RNA metabolism was discovered by 
Barzilay et al. (1995) where the RNase H activity of APE1 was demonstrated. However, this 
alone was not able to convince other researchers who were very skeptical about APEl's new role. 
It was the next discovery of the interaction and association of APE1 with ribosome that slowly 
led scientists to view APE1 differently (Duguid et al. 1995). So far, APE1 has been found to 
interact with a number of other protein factors involved in RNA metabolism and they can be 
divided into five groups of proteins that fall into different areas of RNA metabolism (Table 2). 
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The first group of proteins, hS3 and YB-1, are involved in recognition of damaged 
nucleic acids including RNA (Table 2). Both proteins are known to bind to 8-oxoguanine (8-oxo-
G) residues, ssRNA, and RNA molecules. They are thought to protect RNA molecules from 
degradation or recruit other proteins for repair (Hedge et al. 2004 and Chattopadhyay et al. 
2008). Proteins involved in pre-mRNA maturation or splicing are the next group. These include 
hnRNP-L, PRP19, and MEP 50 (Table 2). Since hnRNP-L exists as a complex of hnRNPs and 
hnRNAs (Pinol-Roma et al. 1989 and Dreyftiss et al. 1993), it has been of no surprise when 
APE1 was discovered to have an association with RNA polymerase II which synthesizes 
hnRNAs in the nucleus (Sengupta et al. 2011). This RNA polymerase II involved in RNA 
synthesis of pre-mRNA, snRNA, and microRNA is the third group of protein associated with 
APE1 (Table 2). Proteins that are involved in rRNA metabolism or ribosome biogenesis (NPM1, 
RSSA, and RLA0) are the fourth group (Table 2). Lastly, PRPS1 and PRPS2 that are involved in 
general ribonucleotides metabolism and synthesis are the fifth group (Table 2). 
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Table 2. List of APE1 interacting proteins found in the literature. 
Protein Functions Reference 
Proteins 
involved in 
recognition of 
damaged RNA 
hS3 Binding to 8-oxo-G residues of RNA 
Binding to ssRNA 
Hedge et al. 2004 
YB-1 
Binding to ssRNA and RNA molecules 
Protection of mRNA from degradation 
Binding to 8-oxo-G containing RNAs 
Chattopadhyay et 
al. 2008 
Proteins 
involved in 
pre-mRNA 
maturation or 
splicing 
hnRNP-L 
Pre-mRNA splicing 
Regulation of chromatin modification Kuninger et al. 2002 
PRP19 DNA double-strand break (DSB) repair 
Pre-mRNA splicing Vascotto et al. 2009 
MEP50 
Component of the 20S PRMT5 
containing methyltransferase complex, 
which modifies specific arginines to 
dimethylarginines in several spliceosomal 
Sm proteins 
Vascotto et al. 2009 
Protein 
invoved in 
RNA synthesis 
RNA 
polymerase 
II 
Catalysis of DNA transcription 
Synthesis pre-mRNA and most snRNA 
and microRNA. 
Sengupta et al. 2011 
Proteins 
involved in 
rRNA 
metabolism or 
ribosome 
biogenesis 
NPM1 
Assembly and transport of ribosomal 
protein 
Control of centrosome duplication 
Regulation of the tumor suppressor ARF 
Vascotto et al. 2009 
RSSA Member of the ribosomal protein S2P family Vascotto et al. 2009 
RLAO Acidic ribosomal protein, rich in hydrophobic amino acid residues Vascotto et al. 2009 
Proteins 
involved in 
general 
ribonucleotides 
metabolism 
and synthesis 
PRPS1 
Catalysis of the phosphoribosylation of 
ribose 5-phosphate to 5-phosphoribosyl-
1-pyrophosphate, which is necessary for 
the de-novo and salvage pathways of 
purine and pyrimidine biosynthesis 
Vascotto et al. 2009 
PRPS2 Ribose metabolism Vascotto et al. 2009 
Altogether, these interactions and associations of APE1 with different protein factors 
involved in RNA metabolism suggest a direct involvement of APE1 in RNA metabolic 
pathways. However, it is still unclear which specific activities of APE 1 can be exerted with the 
association of these proteins and how these affect the overall metabolism of RNAs. 
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1.3.2 Discovery of abasic RNA incision activity and its role in rRNA control 
The second evidence of the involvement of APEl in RNA metabolism was first 
highlighted by Berquist et al. (2008) when they showed APEl's ability to cleave abasic ssRNA 
molecules. However, this alone was insufficient to prove APEl as a novel RNA cleansing 
protein since researchers was not able to address whether the formation of abasic RNA 
molecules is a spontaneous or guided process and whether the damaged RNAs were significant 
enough to cause defect in general protein synthesis (Berquist et al. 2008). 
Interestingly, the N-terminal region of APEl was discovered to interact with NPMl and 
regulate rRNA metabolism within nucleoli (Vascotto et al. 2009). The five lysine residues, K24, 
K25, K27, K31 and K32, are involved in the interaction of APEl with both RNA and NPMl 
(Fantini et al. 2010). By binding to the N-terminal region of APEl required for stable RNA 
binding, NPMl reduces abasic ssRNA incision activity of APEl. In contrast, disruption of the 
APEl-NPMl interactions increases the activity of APEl (Tell et al. 2010). It was also found that 
oxidized rRNA such as 8-oxo-G rRNA was accumulated in APE 1-depleted cells and caused 
impaired translation, lowered intracellular protein content and decreased cell growth rate 
(Vascotto et al. 2009). It was postulated that after APEl cleaves the damaged rRNA, exosome 
complex and XRN1 exoribonuclease may degrade the resulting RNA fragments (Tell et al. 
2010). 
The aforementioned findings demonstrated that APEl can recognize and cleave abasic 
RNA, affect cell growth through its involvement in rRNA control mechanism, play a role as a 
novel RNA cleansing enzyme, and affect gene expression through post-transcriptional 
mechanisms (Vascotto et al. 2009 and Tell et al. 2010). 
18 
CHAPTER 1- INTRODUCTION 
1.3.3 Discovery of endoribonuclease activity of APEl and its role in the control of mRNA 
half-life 
The third evidence for the involvement of APEl in RNA metabolism was discovered by 
Barnes et al. (2009) who identified APEl as an endoribonuclease that specifically cleave in 
between the single stranded regions of UA, CA, and UG dinucleotides at a specific coding region 
of c-myc mRNA termed the coding region determinant (CRD) in vitro. The knock-down of 
APEl in HeLa cells led to an increased steady-state c-myc mRNA levels and half-life (Barnes et 
al. 2009), suggesting that APEl may control c-myc mRNA degradation in cells. In addition, 
another study also showed APEl can cleave CD44 mRNA, micro RNA (miR-21 and miR-lOb), 
and three RNA components of SARS-corona virus (orflb, orfi, spike) in vitro (Kim et al. 2010). 
They also reported that APEl can reduce the ability of the Dicer enzyme to process pre-miRNAs 
in vitro (Kim et al. 2010); however, its activity against all these RNA substrates in vivo are yet to 
be demonstrated. 
It was suggested that the RNA cleaving activity of APEl utilizes the same active site as 
the abasic DNA incision activity since because both E96A and H309N APEl mutants were 
almost inactive in cleaving the RNA template (Barnes et al. 2009). Further site-directed 
mutagenesis studies on APEl active site using N68A, D70A, Y171F, D210N, F266A, D308A, 
and H309S confirmed that APEl shares the same active site for both abasic DNA incision 
activities and RNA cleaving activity (Kim et al. 201 lb). However, these APEl mutants retained 
their ability to bind the RNA substrate, required 2'-OH on the sugar for cleavage, and did not 
require presence of a divalent ion unlike abasic DNA incision activity of APEl (Kim et al. 
2011). Therefore, it was postulated that although APEl shares the same active site, they may 
have different mechanisms for cleaving RNA, abasic ssRNA, and abasic DNA. 
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These results demonstrate APE1 as an endoribonuclease that has the potential to 
influence the stability of mRNAs, microRNAs, and SARS-corona virus RNAs and provide 
further support for its role in the control of RNA metabolism. 
1.4 Role of APE1 in cancer 
1.4.1 Possible role of APE1 in cancers 
APE1 is a multi-functional enzyme that has abasic DNA incision, redox regulation, 3' 
DNA phosphatase, 3' DNA phosphodiesterase, 3'-5' DNA Exonuclease, NIR, transcriptional 
repressor, and RNase H activities. The abasic DNA incision activity of APE1 in BER pathway is 
very well studied and this activity is one of the main functions of APE1. 
Currently, chemotherapy and radiation therapy are selected as one of the main ways to 
treat cancers and these are based on creating DNA damage which leads to an impaired cell 
signaling and eventual death (Helleday et al. 2008). For normal cells, this DNA repair pathway is 
required for spontaneous oxidative stresses that all aerobic organisms are exposed to. However, 
any defect in a specific DNA repair pathway in cancer cells can lead to an abnormally efficient 
DNA repairs and reduce the effect of cancer therapy (Bapat et al. 2009). APE1, an important 
component of BER pathway, is known to contribute to the maintenance of genetic integrity by 
repairing abasic DNA and regulating apoptosis by activating transcription factors. Therefore, 
defect in APE1 activities or altered expressions of APE1 are associated with cancer proliferation 
and can influence the sensitivity of the tumor cells to therapeutic reagents (Bapat et al. 2009). 
Some of examples are the correlations demonstrated between high APE1 levels and the 
resistance of head and neck cancers (Koukourakis et al. 2001), glioma cells (Bobola et al. 2004) 
and medulloblastoma (Bobola et al. 2005), osteosarcoma (Wang et al. 2004), and primitive 
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neuroectodermal tumors (Bobola et al. 2004) to chemo/radiotherapy. Another good example 
illustrating this point is targeting the DNA repair activity of APEl as a cancer treatment strategy 
when patients were treated with clinically relevant DNA damaging chemotherapeutic agents 
such as bleomycin, carmustine, temozolomide (TMZ), and gemicitabine (Madhusudan et al. 
2005, and Luo and Kelley 2004). All of these resulted in a reduced APEl activity, decreased cell 
proliferation, and increased apoptosis and hypersensitivity. Many studies have also shown an 
increased hypersensitivity of APEl knock-down cancer cell lines to chemotherapeutic agents. 
Providing further support for these findings were studies in animal models using anti-sense 
oligonucleotides (reviewed in Fishel and Kelley 2007). 
1.4.2 Relationship of APEl human population variants and cancers 
Interestingly, researchers have found the correlation of APEl polymorphisms with many 
diseases including cancers (Wilson et al. 2011). Polymorphism of APEl, high frequencies of 
inherited DNA sequence variants, is found in the human population. The DNA polymorphism of 
APEl has been under intensive investigation because of the association of polymorphic APEl 
genes with the development of cancers of the bladder (Figueroa et al. 2007), breast (Rossner et 
al. 2006), esophagus (Zhai et al. 2009), lung (Li et al. 2011) and cervix-uterine (Cheng et al. 
2009). The major sequence variants identified in APEl gene and their function changes are 
summarized and shown in Figure 2. 
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Figure 2. Summary of APE1 population variants. Q51H and D148E are polymorphic variants 
and L104R, E126D, R237A/C, and D283G are associated with disease and reduced 
endonuclease function (Hadi et al. 2000 and Wilson et al. 2011). P112L is associated with 
disease. K35Q, G39E, G57A, I64V/T, G241R, G306A, P311S, T313A, and A317V are variants 
with normal endonuclease function (Wilson et al. 2011). 
Sequence variants that are located on the surface of the APE1 endonuclease domain were 
predicted to be damaging to its function (Hadi et al. 2000). D148E APE1 is the population 
variant with the highest observed frequency of -46% (Tomkins et al. 2000). D148E was 
predicted to have no impact on the structure or function such as abasic DNA incision activity but 
the cancer cells carrying this mutation showed hypersensitivity to ionizing radiation (Hu et al. 
2001). Other studies have shown the association of D148E polymorphism to various cancer risks 
in the human population but there are also studies which showed no such associations (Hung et 
al. 2005, Jiao et al. 2006, Bartsch et al. 2007, Lo et al. 2009, Deng et al. 2010, and Ji et al. 
2011). There is no identified associated risk for Q51H but I64V has been associated with a 
decreased lung cancer risk (Zienolddiny et al. 2006). 
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Abasic DNA endonuclease activity of population variants of APE1 has been previously 
reported. L104R, E126D, R237A, and D283G were found to exhibit about 40-60% reductions in 
specific abasic DNA cleaving activity whereas no defect in endonuclease activity was found in 
D148E, G241R, and G306A variants (Hadi et al. 2000). In contrast, recent work by Dr. Lee's lab 
discovered that D148E, Q51H, I64V, G241R, R237A, and G306A, exhibited 76-85% reductions 
in endoribonuclease activity against a specific coding region of c-myc RNA (Kim et al. 2012). 
Interestingly, both L104R and E126D variants exhibited endoribonuclease activity which is 
distinct from the WT-APE1 (Kim et al. 2012). Further studies on APE1 polymorphisms in an 
effort to discover their effects on protein structure, nuclease activities, redox (REF-1) regulatory 
function, intracellular distribution should be undertaken in order to gain a better understanding of 
the correlation of APE 1 polymorphisms and cancer risks. 
1.4.3 Relationship of cellular localization of APE1 and cancers, and proposed functions of 
APE1 in each cellular compartment 
Most reports demonstrate that APE1 localizes to the nucleus to carry out its abasic DNA 
incision and redox regulatory activities (Tell et al. 2005). However, there are number of 
immunohistochemical studies on APE1 localization reporting differences in APE1 sub-cellular 
localization in different cell types including cancers (Duguid et al. 1995, Kakolyris et al. 1997, 
Kakolyris et al. 1998a, Kakolyris et al. 1998b, Kakolyris et al. 1999, Puglisi et al. 2001, Kelley 
et al. 2001, and Di Maso et al. 2007). Altered localization of APE1 from nucleus to cytoplasm 
shown by stains in various tumors has been well-documented (Evan et al. 2000 and Tell et al. 
2005). This cytoplasmic expression of APE1 is correlated with more aggressive carcinomas and 
a poor prognosis for the patients (Tell et al. 2010). This has led to the speculation of yet 
undefined extra-nuclear roles of APE1 and its potential implications in cancer development. In 
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this section I will review mechanisms that are known to control APEl localization and the 
cytoplasmic localization of APE 1 in regards to its functions and associations with cancers. 
1.4.3.1 Mechanisms that control APEl localization 
APEl like any other cellular proteins gets translated in the cytoplasm and then 
translocated to the nucleus. This nuclear localization of APEl is controlled by the nuclear 
localization signal (NLS) at its N-terminus. The NLS is composed of first 20 amino acids and is 
an unstructured sequence which uses karyopherin al and a2 for its translocation (Jackson et al. 
2005). This region of APEl is also important for abasic RNA binding and is involved in protein-
protein interactions that are devoted to redox-mediated transcriptional co-activation activity 
(Vascotto et al. 2009). It was proposed that Granzyme A cleaves APEl at Lys31 and this results 
in APEl missing the first 33 amino acid residues (ND33-APE1) (Fan et al. 2003). In turn this 
alters APEl accumulation within the nucleus (Fan et al. 2003 and Jackson et al. 2005). There is 
also a finding which reported proteolysis occurring at residue Asn33 rather than Lys31 
(Chattopadhyay et al. 2006). The proteolysis at the 33rd residue of APEl may be a general 
molecular device for redirecting APEl to mitochondria (Tell et al. 2001) and this is supported by 
the discovery that showed mitochondrial APEl (mtAPEl) as a truncation product of APEl. The 
truncated APEl does not have the first 33 N-terminal residues in bovine liver, mouse liver, and 
NIH 3T3 cell line (Chattopadhyay et al. 2006). Given that mtAPEl lacks the N-terminal domain 
which aids in BER pathway by enhancing abasic DNA binding and interactions with other repair 
protein, it is considered not to be involved in interactions with other proteins for DNA repair in 
the mitochondria (Mitra et al. 2007). 
There also may be a nuclear export signal (NES) of APEl that regulates APEl 
translocation from the nucleus to the cytoplasm. The nuclear accumulation of APEl after 
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treatment with the nuclear export inhibitor Leptomycin B was observed and it suggested the 
presence of a NES that is near a Leu-rich region at the C-terminus (Jackson et al. 2005). They 
noted three leucine residues, Leu291, Leu292, and Leu295 residues, which are exposed in the 
surface of the APE1 3D structure and modification of these residues might have caused nuclear 
accumulation (Jackson et al. 2005). Others have suggested that the two cysteine residues of 
APE1, Cys93 and Cys310, can undergo S-nitrosation in response to a nitric oxide stimulation 
and this can lead to the export of APE1 in a CRM 1-independent process (Qu et al. 2007). It has 
been suggested that APE 1 has a NES at the 64-80 amino acid residues and along with these two 
cysteine residues, they are responsible for re-localization of APE1 to the cytoplasm (Qu et al. 
2007). 
Lastly, the interaction with specific nuclear proteins can be a possible mechanism for 
APE1 nuclear distribution. Jung et al. (2007) found that the nuclear localization of APE1 was 
regulated by the GAFF45a nuclear protein expression. However, further study on the 
downstream mechanism of this nuclear import of APE1 is required. 
1.4.3.2 Cytoplasmic localization of APE1. its proposed functions, and its relationship 
with cancers 
The cytoplamic localization of APE1 has been noted in cells that have high metabolic or 
proliferactive rates such as spermatocytes, thyrocytes, lymphocytes, heptocytes, and 
hippocampal cells (Duguid et al. 1995, Kakolyris et al. 1998, Kakolyris et al. 1997, Rivkees and 
Kelley 1994, Tell et al. 2000, and Wilson et al. 1996). Other cell types are known to exhibit both 
nuclear and cytoplasmic localization of APE1 and these include normal thyroid cells stimulated 
by TSH, transformed thyroid cell, mucosal and parietal cells of the stomach, cerebellar Purkinje 
cells, adrenal cortical cells, and some cervical cells (Tell et al. 2000, Kakolyris et al. 1998a, and 
Rivkees and Kelley 1994). The cytoplasmic APE1 is thought to have two main roles in the 
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cytoplasm. Firstly, as a mtDNA repair device in mitochondria upon oxidative stress (Rivkees and 
Kelley 1994 and Wilson et al. 1996). Secondly, as an ER stress response device where it induces 
apoptosis (Fan et al. 2003). Maintaining newly synthesized transcription factors in a reduced 
state prior to their transport to the nucleus is another proposed role for cytoplasmic APE1 (Mitra 
et al. 2006). 
Recently, APEl's role in RNA metabolism has been highlighted (Barnes et al. 2009 and 
Tell et al. 2010). The involvement of the rRNA and mRNA control mechanisms may explain the 
cytoplasmic localization of APE1. Therefore, it appears that sub-cellular localization of APE1 
may be governed by a strictly regulated process and the biological relevance of the APE1 
localization clearly requires further investigations. 
Researches have reported complex localization of APE 1 in various tumors and these have 
been well-reviewed (Evan et al. 2000 and Tell et al. 2005). The nuclear/cytoplasmic and 
cytoplasmic expressions of APE1 in these tumors are also found to be correlated with more 
aggressive carcinomas and a poor prognosis for the patients. For instance, the cytoplasmic 
localization of APE1 in hepatocellular carcinoma (HCC) was associated with a significant lower 
degree of differentiation and with a shorter survival time (Di Maso et al. 2007). Similarly in 
epithelial ovarian cancer, correlations between the cytoplasmic localization of APE1 and low 
tumor differentiation, significantly higher stage, and lower survival rate were found (Sheng et al. 
2011). All these findings suggest that cytoplasmic localization of APE1 is associated with tumor 
progression and APE1 may be used as a prognostic marker for aggressive cancers. 
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1.5 Research objectives 
Although, there is increasing number of studies that investigated the possible link 
between the role of APEl and its cytoplasmic localization no consensus has been reached. This 
has led to the speculation of yet undefined extra-nuclear roles of APEl and its potential 
implications in cancer development. As a result, the role of APEl in mRNA and rRNA 
metabolism has been recently highlighted (Tell et al. 2010). Recent works has shown that APEl 
is capable of cleaving abasic RNA (Berquist et al. 2008) and physically associate with a nuclear 
protein NPM1, known to be involved in ribosomal RNA processing (Vascotto et al. 2009). This 
finding also supports the identification of APEl as an endoribonuclease that may play a role as a 
cytoplasmic regulator of RNA metabolism (Barnes et al. 2009). In order to further understand the 
involvement of APEl in RNA metabolism in the cytoplasm and the possible biological 
significance, the following research objectives were established. 
The first objective was to confirm the cellular localization of wild-type and N-terminal 
deletion variants of APEl. In addition, the objective was to identify the cellular localization of 
APEl human population variants. To accomplish this, we generated the APE1-GFP fusion 
proteins in order to visualize them in live cells of HeLa and HepG2. Visualization of the wild-
type and N-terminal deletion variants of APEl were expected to confirm the role of nuclear 
localization signal of APEl located in the N-terminus. Also, we intended to assess the cellular 
localization of APEl human population variants. To date, there has been no reports on the 
localization of APEl human population variants nor was there reports on localization of APEl 
ND20-population mutants. Therefore, our results from the analysis of the expression of APE1-
population variants-GFP in HeLa and HepG2 cells are expected to reveal if there is a relationship 
between their sub-cellular localization and role in diseases. 
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The second objective is to identify the cellular localization of wild-type, N-terminal 
deletion, and human population variants of APEl under cellular stress. We were particularly 
interested in assessing the possible co-localization of APEl with processing bodies and stress 
granules which are well-established mRNA degradation locales. The results are expected to 
reveal the re-distribution of APEl under stress conditions and the involvement of APEl in RNA 
metabolism carried out in the processing bodies and stress granules. We also preliminarily 
investigated APEl distribution in the breast cancer tissue and its co-localization with processing 
bodies and stress granules. The results are expected to provide an insight of APEl distribution in 
the breast cancer. 
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Cellular localization of wild-type, N-terminus deleted APEl, and population 
variants 
2.1 Introduction 
This chapter presents the experiments conducted to determine the cellular localization of 
wild-type APEl, N-terminal deletion variants, and population variants of APEL To date, there 
has been no report on localization of APEl population variants nor were there reports on 
localization of APEl ND20-population variants. Therefore, it is intriguing to evaluate the 
localization of APEl and its population variants in HeLa and HepG2 cells. 
2.2 Methodology 
This section describes the methods employed in investigating the cellular localization of 
wild-type APEl, N-terminal deletion variants, and population variants of APEl in HeLa and 
HepG2 cells. 
2.2.1 Primer design 
The following primers were designed to amplify APEl cDNA from pFLAG-CMV-5.1 
(4.7Kbp) vector (Table 3). Restriction sites of EcoRI and BamHI were incorporated for cloning 
of APEl cDNA into pEGFP-Nl vector. These primers were generated by Integrated DNA 
Technologies (IDT) and were dissolved in autoclaved water to yield the concentration of 300 
pmol/nl. 
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Table 3. Sequences of primers used to amplify APE1 cDNA. Underlined text indicate where 
mutations were introducec 
Primer name Primer sequences 
APEl-EcoRI-F 5' -ACC A GAA TTC AT ATG CCG AAG CGT GGG AAA-3 ' 
APE 1 -ND20-EcoRI-F 5'-ACC A GAA TTC ATG CCA GAG GCC AAG AAG AGT 
AAG A-3' 
APE 1-ND41 -EcoRI-F 5'-ACC A GAA TTC ATG CCA GCC CTG TAT G-3' 
APE 1 -BamHI-R-no 
stop 
5'-ACC A GGA TCC ATC AGT GCT AGG TAT GGG TGA 
TGA G-3' 
2.2.2 PCR amplification of WT APE1 and ND variants 
To prepare cDNA for sub-cloning APE1, the pFLAG-CMV-5.1-APEl was used as the 
template for PCR. A total reaction mixture of 25 |*1 contained 100 ng of pFLAG-CMV-5.1 
plasmids, 1 fil of Phusion DNA polymerase (Finnzymes), 0.2 mM dNTPs, IX Phusion HF 
reaction buffer (Finnzymes), 0.4 pmoles of forward and reverse primers. The mixture was put 
into the PCR MiniCycler PCR machine (MJ Research Inc., Watertown, MA) which was 
programmed to incubate the mixture at 95°C for 2 min, and for 30 cycles of 30 sec at 95°C, 30 
sec at 55°C, and 1 min at 72°C. It was then incubated for 10 min extension at 72°C and held at 
4°C. Once the PCR was finished, the mixture containing amplified cDNA was added with 2 |xl of 
agarose loading dye and run in 1 % agarose gel for 1 hour at 100V in 0.5X TBE buffer. The PCR 
fragment was visualized under UV light and excised using a scalpel. The PCR fragment was 
purified using QIAEX II Gel Extraction Kit (Qiagen Inc., Valencia CA) and following the 
manufacturer's protocol. 
2.2.3 Restriction Digestion of PCR products and plasmids 
The purified PCR fragments of APE1 cDNA was digested using EcoRI and BamHI. The 
pEGFP vector was linearized using the same enzymes. A 20 |xl digestion reaction contained 1 -3 
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Hg of plasmids or PCR products, 1 jj.1 of EcoRI and BamHI (lOU/jul), lx reaction bufer (ReACT 
3 from Invitrogen), 0.1 |ig/(il BSA, and made up to volume with autoclaved water. The digestion 
was carried at 37°C for 1 hour. After digestion, 1 |il of 1 kb DNA ladder (Invitrogen), all of 
linearized samples, and 1 |jl of uncut plasmids were loaded onto 1% agarose gel to check for 
completion of the reaction. The gel was run for 1 hour at 100 V in 0.5X TBE buffer and 
visualized under UV light and the bands were excised. Each DNA band was purified using 
QIAEX II Gel Extraction Kit (Qiagen Inc., Valencia CA). 
2.2.4 Sub-cloning WT-APE1 and APE1 ND variant cDNAs into pEGFP plasmid 
The purified digested APE1 cDNA and pEGFP vector were ligated in a reaction mixture 
of 20 |il containing lx Ligation Buffer (Invitrogen), 4 fil of linearized pEGFP vector, 8 JJ.1 of cut 
APEl cDNA, l fil of T4 DNA ligase (Invitrogen), and made up to volume with autoclaved 
water. The reaction was incubated at room temperature for 2 hours. 
Tubes of 100 |il DH5a bacteria from -80°C freezer were thawed on ice for 5 min. All of 
the 20 (il ligation reaction was transferred to each tube of bacteria and the bacteria were 
incubated for 25 min on ice. They were heat-shocked for 90 sec at 42°C in the water bath and 
then cold-shocked for 2 min on ice. To each tube, 500 |il of LB was added and it was incubated 
for 30 min at 37°C in the water bath. Each transformed bacteria was plated onto the agar plate 
containing appropriate antibiotic, Kanamycin (25 (jg/ml), and was incubated at 37°C incubator 
overnight. 
2.2.5 Mini plasmid preparation to isolate pWT-APEl, pND20, and pND41 
A single colony was picked from the plate and was grown overnight at 37°C with shaking 
in a 50 ml falcon tube. The tube contained 10 mL of LB and the appropriate antibiotic, 
Kanamycin (25 jig/ml). The next day, the culture was split in 7 eppendorf tubes and was 
31 
CHAPTER 2- CELLULAR LOCALIZATION OF WILD-TYPE, N-TERMINAL 
DELETION, AND POPULATION VARIANTS OF APE1 
centrifiiged for 2 min at 12,000 rpm. The cells were pelleted and the supernatant was removed by 
pipetting. The pEGFP-APEI (pWT-APEl), pEGFP-ND20 (pND20), and pEGFP-ND41 
(pND41) vectors were then purified using QIAprep® Spin Miniprep Kit (250) (Qiagen, Hilden, 
Germany) and following the manufacturer's protocol. The concentrations of purified plasmids 
pWT-APEl, pND20, and pND41 vectors were measured using the NanoDrop 1000 UV/Vis 
(Thermo Scientific, Wilmington, DE). Plasmid sequences were confirmed by DNA sequencing 
at Macrogen Inc. (Seoul, Korea). The data can be found in the Appendix. 
2.2.6 Generation of APE1 population variants using pWT-APEl vector 
To generate population APE1 variants from pWT-APEl vector, the following primers 
were used in site-directed mutagenesis (Table 4). These primers were synthesized by Integrated 
DNA Technologies (IDT) and were dissolved in autoclaved water to a final concentration of 300 
pmol/|il. The pWT-APEl vector containing cDNAs of APE1 was amplified via PCR using each 
set of primers. 
Table 4. Sequences of forward and reverse primers to generate population APE1 variants using 
Primer name Primer sequences 
164 V-F 
I64V-R 
5' GCC ACA CTC AAG GTC TGC TCT TGG AAT-3' 
5'-ATT CCA AGA GCA GAC CTT GAG TGT GGC-3' 
L104R-F 
L104R-R 
5'-TCA GAG AAC AAA CGA CCA GCT GAA CTT-3' 
5'-AAG TTC AGC TGG TCG TTT GTT CTC TGA-3' 
E126D-F 
E126D-R 
5'-CCT TCG GAC AAG GAC GGG TAC AGT GGC-3' 
5'-GCC ACT GTA CCC GTC CTT GTC CGA AGG-3' 
D148E-F 
D148E-R 
5'-TAC GGC ATA GGC GAA GAG GAG CAT GAT-3' 
5'-ATC ATG CTC CTC TTC GCC TAT GCC GTA-3' 
G306A-F 
G306A-R 
5'-TCC AAG GCC CTC GCC AGT GAT CAC TGT-3' 
5'-ACA GTG ATC ACT GGC GAG GGC CTT GGA-3' 
D308A-F 
D308A-R 
5'-GCC CTC GGC AGT GCT CAC TGT CCT AT-3' 
5'-G GAG CCG TCA CGA GTG ACA GGA TAG-5' 
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2.2.7 Site directed mutagenesis to generate pWT-APEl population variants and pND20-
population variants 
To generate pAPEl population variants, the pWT-APEl vector was amplified via PCR 
using each set of primers for each population variants of APE1. The pND20 vector was used for 
the generation of pND20-population variants. A total reaction mixture of 50 p.1 contained 100 ng 
of either pWT-APEl or pND20 plasmids, 1 fil of Phusion DNA polymerase (Finnzymes), 0.2 
mM dNTPs, lxPhusion HF reaction buffer (Finnzymes), 0.4 pmoles of forward and reverse 
primers. The mixture was put into the PCR MiniCycler PCR machine (MJ Research Inc., 
Watertown, MA) which was programmed to incubate the mixture at 95°C for 2 min, and for 18 
cycles of 45 sec at 95°C, 45 sec at 55°C, and 10 min at 72°C. Then it was incubated for 20 min 
extension at 72°C and hold at 4°C to finish generating vectors. Once the PCR was finished, the 
mixture was added with 5 jxl of agarose loading dye and run in 1% agarose gel for 1 hour at 100 
V in 0.5X TBE buffer. The PCR fragment was visualized under UV light and excised. The PCR 
fragment was purified using QIAEX II Gel Extraction Kit (Qiagen Inc., Valencia CA). 
The purified vectors were transformed with 100 (il DH5a bacteria by heat-shock and 
plated on Kanamycin (25 fig/ml) plates. Three colonies for each vector were picked. Plasmids 
were isolated using the QIAprep® Spin Miniprep Kit (250) (Qiagen, Hilden, Germany) and 
following the manufacturer's protocol. Then the concentrations of purified vectors were 
measured using the NanoDrop 1000 UV/Vis (Thermo Scientific, Wilmington, DE). Plasmid 
sequences were confirmed by DNA sequencing performed at Macrogen Inc. (Seoul, Korea). 
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2.2.8 Assessing the localization of WT-APE1-, ND20-, ND41-, and population variants-GFP 
Cell culture and reagents 
HeLa and HepG2 cells were cultured in a tissue culture flask (T25CN) (Sarstedt, Newton, 
NC) with 10 ml of Minimum Essential Medium (MEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10 % fetal bovine Serum (FBS). The cells were incubated under 5 % C02 and 
at 37 °C. Maintenance of cells were done by splitting the cells in 1:10 ratio into a fresh T25 flask 
approximately after three days of growth or when the cells have reached a confluency of 80-90 
%. To plate cells on the 2-chambered cover-glass slide, cells in the T25 flask were washed with 2 
ml of PBS pH 7.4 (Invitrogen, Carlsbad, CA) and subsequently treated with 1 ml of 0.25 % 
Trypsin-EDTA (Invitrogen, Carlsbad, CA) and incubated at 37 °C and 5 % CO2 for 2 min. Then, 
9 ml of MEM was added to the cells. Cells were separated by pipetting up and down. To 
determine cell count, about 30 fil of cells were taken and mixed with equal volume of Trypan 
Blue dye (Sigma) and the number of cells in the 16-square quadrant of the Bright Line 
hemacytometer (Hausser Scientific, Horsham, PA) was counted. From the average number of the 
cells counted, the cell concentration in the T25 flask was determined and the cells were diluted to 
2.5 x 104 cells/ml and were plated at 2 ml onto each chamber. The plated cells were grown for 24 
hours at 37 °C and 5 % C02 before transfection. 
Transfection 
Before transfection, the media was replaced with 1.5 ml of fresh MEM containing 10% 
FBS. A mixture of 1.2 (il of Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) and 148.8 
fil of OPTI-MEM (Invitrogen, Carlsbad, CA) was prepared and incubated at room temperature 
for 5 min. Another mixture of 0.75 |ig (for HeLa cells) and 1 fig (for HepG2 cells) of each vector 
and 150 nl of OPTI-MEM was prepared and incubated at room temperature for 5 min. The 
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mixture of 150 |il OPTI-MEM and Lipofectamine 2000 Reagent was added to the 150 (il of the 
vector and OPTI-MEM mixture, shaken vigorously, and incubated at room temperature for 20 
min. The final 300 [il mixture was added to each chamber of the cover-glass slide. The cells were 
grown for a further 48 hours at 37 °C and 5 % CO2 before they were viewed under the 
FluoView™ FV1000 Confocal Microscope (Olympus America INC., Merville, NY). 
Confocal Microscopy 
Before viewing the cells, media was changed to fresh media and the living cells were 
viewed under the microscope. Images were collected using the microscope in sequential mode 
using a 20X dry lens (lens specification, UPlanFI 20x / NA 0.50 00/-) at subsequent zoom-in 
mode of IX or 2X using Multi-line Ar laser (457 nm, 488 nm, 515 nm, Total 30 m). Images were 
exported from the FV1000 confocal software into a JPEG file with a resolution of 1024 X 1024. 
No image manipulation was performed to generate the figures. 
2.3 Results and Discussion 
2.3.1 Cellular localization of WT-APE1-, ND20-, and ND41-GFP in HeLa and HepG2 cells 
Upon exposure of WT-APE1-GFP in both HeLa and HepG2 cells, the fluorescence was 
localized to the nucleus (Figure 3A and 3D). This was expected and consistent with previous 
reports (Ramana et al. 1998; Duguid et al. 1995) as APE1 has well established roles in the 
nucleus such as abasic DNA cleaving activity. Therefore, when the generated plasmids of WT-
APE1-GFP were transiently expressed in both HeLa and HepG2 cell lines, the fusion protein 
WT-APE1-GFP showed nuclear localization (Figure 3A and 3D). 
Various sub-cellular localization of APE1 has been documented in the literature (Duguid 
et al. 1995; Kakolyris et al. 1997; Kakolyris et al. 1998a; Kakolyris et al. 1998b; Kakolyris et al. 
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1999; Puglisi et al. 2001; Kelley et al. 2001; Maso et al. 2007). This localizations have been an 
enigmatic phenomena. Interestingly, many DNA repair proteins including APE1 are known to be 
present in both the nucleus and cytoplasm. This is due to the proteins being transiently targeted 
to the nucleus and mitochondria in response to DNA damage signals (Mitra et al. 2002). Jackson 
et al. (2005) found that APE1 has two known independent nuclear localization signals. A 
canonical NLS is composed of the first seven residues at the N-terminus and the amino acid 
stretch of residues between 8 and 13 (Jackson et al. 2005). In the absence of N-terminal region, 
APE1 has been known to exhibit cytoplasmic localization (Jackson et al. 2005). This finding was 
of interest to Chattopadhyay et al. (2006) who found that APE1 can undergo hydrolysis during 
boiling of the protein samples. The hydrolysis results in APE1 losing its N-terminal region of 32-
33 amino acids. Accordingly, the mitochondrial APE1 (mtAPEl) is a truncated product of APE1 
missing 33 N-terminal residues (Chattopadhyay et al. 2006). It was also postulated that 
Granzyme A cleaves APE1 at Lys31 and blocks stable interaction with other proteins for DNA 
repair. The blockage results in a truncated form of APE1 in mitochondria (Chattopadhyay et al. 
2006). Therefore, when the ND20-GFP and ND41-GFP were expressed in both HeLa and 
HepG2 cells, they were localized to both the nucleus and the cytoplasm (Figure 3B-3F). This 
was consistent with the findings by Jackson et al. (2005). However, it was difficult to observe 
the mitochondrial localization of ND20-GFP and ND41-GFP since we did not implement any 
mitochondrial tracker. Also, determining the mitochondrial localization of APE1 was not the 
objective of this experiment. It should be pointed out that Chattopadhyay et al. (2006) used 
HEK293 human kidney cells, while we used HeLa and HepG2 cells. This may also be a 
contributing factor why we did not observe any localization of WT-APE1 GFP to the 
mitochondria. 
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Figure 3. Expression of the fusion proteins, APE1-, ND20- and ND41-GFP, in HeLa and 
HepG2 cells. HeLa and HepG2 cells were plate on 2-chamber slide at 5X104 cells/ml. After one 
day in culture, cells were transfected with 1 ng of plasmid using Lipofectamine reagent. Cells 
were viewed under the confocal microscope after two days of transfection. (A, B, and C) 
Expressions of pWT-APEl, pND20, and pND41 in HeLa cells. (D, E, and F) Expressions of 
pWT-APEl, pND20, and pND41 in HepG2 cells. The scale bar is for the all images. 
2.3.2 Cellular localization of population variants- and ND20 population variants-GFP in 
HeLa and HepG2 cells 
There are numerous studies investigating the possible association of the human 
population variants of APE1 with increased disease susceptibility (Hung et al. 2005; Jiao et al. 
2006; Bartsch et al. 2007; Pardini et al. 2008; Lo et al. 2009; Deng et al. 2010; Ji et al. 2011). 
However, there has been no study on determining the localization of APE1 variants in cells. In 
this study, we took the initiative to determine the cellular localization of APE1 population 
variants. 
When the GFP fusion proteins of I64V, L104R, E126D, D148E, G306A, and D308A 
were transiently expressed in both HeLa and HepG2 cells, they showed nuclear localization 
similar to that of observed with the WT-APE1-GFP (Figures 4 and 5). All of these population 
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variants are classified as non-synonymous single nucleotide polymophysms (SNPs) because they 
result in a single amino acid change in a protein. This change is often associated with changes in 
gene expression, mRNA conformation and stability, and translational efficiency. For example, 
changing the Pro 111 residue to Ala in Caveolin-1 drastically changed the conformation of the 
protein and prevented the localization of the protein into lipid rafts; thus, preventing the 
functioning of caveolae (Aoki and Epand 2011). They may also play a direct role with or without 
other factors in the phenotypic expression of diseases or in the susceptibility of an individual to 
many common diseases and drug resistance (Shastry 2009). With the exception of L104R and 
E126D, all of the variants that we investigated were found to retain their abasic DNA incision 
activities. This suggests their silent effects on APE1 abasic DNA repair function (Kim 2009). 
Interestingly, when they were assessed for RNA cleaving activity, the variants showed 
significant reduction in activity as compared to the WT-APE1, with the exception of L104R and 
E126D which exhibited different RNA cleaving patterns (Kim et al. 2012). Therefore, we 
anticipated re-distribution of the population variants of APE1, especially L104R and E126D, if 
they were expressed in human cancer cell lines. However, all variants tested showed uniform 
distribution to the nucleus (Figures 4 and 5). These results show that SNPs of APE1 population 
variants do not play a role in APE1 redistribution. It also suggests that APE1 may play a more 
prominent role in the nucleus than in the other compartments of HeLa and HepG2 cells. 
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Figure 4. Expression of population variants-GFP in HeLa cells. HeLa cells were plate on 2-
chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 jig of 
plasmid using Lipofectamine reagent. Cells were viewed under the confocal microscope after 
two days of transfection. Expressions of (A) pI64V, (B) pL104R, (C) pE126D, (D) pD148E, (E) 
pG306A, and (F) pD308A in HeLa. 
Figure 5. Expression of population variants-GFP in HepG2 cells. HepG2 cells were plate on 
2-chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 |ig of 
plasmid using Lipofectamine reagent. Cells were viewed under the confocal microscope after 
two days of transfection. Expressions of (A) pI64V, (B) pL104R, (C) pE126D, (D) pD148E, (E) 
pG306A, and (F) pD308A in HepG2. 
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We also tested the GFP fusion proteins of ND20-population variants. To see if they 
exhibit any different sub-cellular localization when population variants were deliberately 
restricted to the cytoplasm, the variants including ND20-L104R, ND20-E126D, ND20-D148E, 
and ND20-G306A were tested. However, no significant difference in their localization was 
observed for all ND20-population variants as compared to the ND20 (Figures 6 and 7). This re­
confirmed that N-terminal region of APE1 is important for nuclear localization of APE1 and that 
single amino acid change outside of 20 amino acids of the N-terminus does not play any role in 
APE1 localization. 
Figure 6. Expression of ND20 population variants-GFP in HeLa cells. HeLa cells were plate 
on 2-chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 |ig 
of plasmid using Lipofectamine reagent. Cells were viewed under the confocal microscope after 
two days of transfection. (A) Expressions of pND20-L104R, (B) pND20-E126D, (C) pND20-
D148E, (D) pND20-G306A in HeLa. 
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Figure 7. Expression of ND20 population variants-GFP in HepG2 cells. HepG2 cells were 
plate on 2-chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 
1 ng of plasmid using Lipofectamine reagent. Cells were viewed under the confocal microscope 
after two days of transfection. (A and A-1) Expression of pND20-L104R in HepG2 and its DIC 
overlap. (B and B-l) Expression of pND20-E126D in HepG2 and its DIC overlap. (C and C-l) 
Expression of pND20-D148E in HepG2 and its DIC overlap. (D and D-l) Expression of 
pND20-G306A in HepG2 and its DIC overlap. 
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Localization of APE1 under cellular stress 
3.1 Introduction 
This chapter describes the experiments conducted to study the possible co-localization of 
WT-APE1, N-terminal deletion variants and population variants of APE1 with processing bodies 
(PBs) and stress granules (SGs). The decapping enzyme, Dcpla, was used as a PBs marker and it 
was tagged with RFP for live visualization in cells. One of the factors for SGs assembly, TIA-1 
tagged with monomelic RFP (mRFP), was used as a SGs marker. In addition, possible 
mechanism of ND20 re-distribution upon cellular stress was investigated using different cellular 
inhibitors such as nuclear export inhibitor, nuclear import inhibitor, protein systhesis inhibitor, 
and ubiquitin protease inhibitors. Biochemical analysis of exogenous APE1 with and without 
cellular stress was carried out to confirm the immunofluorescence study. Finally, localization of 
APE1 in the formalin fixed and paraffin-embedded (FFPE) breast carcinoma was investigated. 
3.2 Methodology 
3.2.1 Reagents and buffer preparation 
The reagents shown in Table 5 and 6 were used throughout the experiments described in 
this chapter. 
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Table 5. List of chemicals to generate reagents used. 
Final 
concentration Type of stress Stock 
0.5 mM Sodium 
Arsenite (arsenite) Oxidative Stress Stock: 0.5 M (0.156 g in 1 ml of water) 
1 mM S-Nitroso 
glutathione (GSNO) Nitrosative Stress Stock: 0.247 M (0.025 g in 300 |il of water) 
5 nM Leptomycin B 
(LMB) Nuclear export inhibition Stock: 9.25 jiM (5 (ig/ml supplied) 
0.35 mM 
Cycloheximide 
(CHX) 
Protein synthesis inhibition Stock: 0.35 M (0.1 g in 1 ml of DMSO) 
8 |iM Epoxomycin 
(EPO) 
Ubiquitin protease 
inhibiton Stock: 0.4507 mM (50 fig in 200 pi of water) 
50 nM 2,4-
Diaminoquinazoline 
(DQZ) 
Nuclear import inhibition Stock: 0.1 M (0.1 g in 6.243 mL of water) 
8 jxM MG-132 Ubiquitin protease Inhibition Stock: 0.01 M (1 mgin 210 (il of DMSO) 
Table 6. List of buffers to generate reagents used in this chapter. 
Buffers Reagents 
10X PBS (pH 7.4) 1.37 M NaCl, 27 mM KC1, 100 mM Na2HP04, and 20 mM KH2P04 
10X TBS (pH 7.4) 0.2 M Tris-HCl and 1.5 M NaCl 
Blocking buffer 2% Triton X-100, 2% BSA, and IX TBS pH 7.4 
Wash buffer 0.2% Triton X-100, 0.2% BSA, and IX TBS pH 7.4 
3.2.2 Assessing the localization of APEl, N-terminus deleted APEl, and APEl population 
variants undergoing cellular stressors 
Cell culture and transfection 
HeLa and HepG2 cells were cultured and plated following the procedures outlined in 
Chapter 2. The plated cells were grown for 24 hours at 37°C and 5% C02 before transfection. 
For HeLa cells, 0.75 |ig of each vector was used and 1 (ig of each vector was used for HepG2 
cells. The cells were grown for 48 hours at 37°C and 5% CO2 until they were viewed the 
FluoView™ FV1000 Confocal Microscope (Olympus America INC., Merville, NY). 
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Induction of cellular stress 
Before viewing the cells using the confocal microscope, the media were replaced with 1.0 
ml of fresh MEM containing 10% FBS and incubated at 37°C and 5% CO2 for at least 30 min. 
Cells were then exposed to a cellular stressor. For HeLa and HepG2 cells, sodium arsenite (0.5 
mM arsenite for 4hr) and S-Nitroso glutathione (1 mM GSNO for 4hr) were tested. In some 
experiments inhibitors such as Leptomycin B (5 nM LMB for 6hr), Cycloheximide (0.35 mM 
CHX for lhr), Epoxomicin (8 |iM EPO for 6hr), 2,4-Diaminoquinazoline (50 |aM DQZ for 6hr), 
and MG-132 (8 jaM MG-132 for 6hr) were added and arsenite was subsequently added. Cells 
were then viewed under the confocal microscope following the procedures outlined in Chapter 2. 
3.2.3 Generation of pEGFP-ND25, ND30 and ND35 
The following primers were designed to amplify APE1 cDNA from pFLAG-CMV-5.1 
(4.7Kbp) vector (Table 7). Restriction sites of EcoRI and BamHI were incorporated into the 
primers for ease in sub-cloning of APE1 cDNA into pEGFP-Nl vector. These primers were 
generated by Integrated DNA Technologies (IDT) and were dissolved in autoclaved water to 
yield a concentration of 300 pmol/|il. Sub-cloning of each amplified APE1 cDNA was put into 
pEGFP-Nl vector using the previously discussed methods in Chapter 2. Plasmid sequences were 
confirmed by DNA sequencing at Macrogen Inc. (Seoul, Korea) and the sequencing data can be 
found in the Appendix. 
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Table 7. Sequences of primers to amplify APE1 genes from a vector. Underlined texts indicate 
where mutations were introduced. 
Primer name Primer sequences 
APE 1 -ND25-EcoRI-F 5'-ACC AGA ATT CAT ATG AGT AAG ACG GCC GCA 
AAG-3' 
APE 1 -ND30-EcoRI-F 5'- A CCA GAA TTC ATA TGA AAG AAA ATG ACA AAG 
AGG CAG CAG GA-3' 
APE1 -ND35-EcoRI-F 5'- A ACA GAA TTC ATC ATG GAG GCA GCA GGA GAG GGC-3' 
APEl-BamHI-R-no stop 5'-ACC A GGA TCC ATC AGT GCT AGG TAT GGG TGA 
TGA G-3' 
3.2.4 Preparation of RFP-Dcpla and mRFP-TIA-1 plasmids 
The Dcpla tagged with RFP was a gift from Dr. Masayuki Murata's laboratory from the 
University of Tokyo. The TIA-1 tagged with mRFP was a gift from Dr. Paul Anderson's 
laboratory from Harvard Medical School. Both plasmids were sent on filter papers containing 
about lOOng of plasmids. The plasmids were extracted by cutting area where the plasmids were 
seeded and the papers were soaked in 100 nl of auto-claved water. After incubation at room 
temperature for 30 min, 1 (j.1 and 10 |il of each plasmid solution were used for transformation 
with 100 ^1 DH5a bacteria by heat-shock method and plated on Kanamycin (25 ng/ml) agar 
plates. Three colonies for each vector were picked and plasmids were isolated using QLAprep® 
Spin Miniprep Kit (250) (Qiagen, Hilden, Germany) as according to the manufacturer's protocol. 
Concentrations of plasmids were determined using the NanoDrop 1000 UV/Vis (Thermo 
Scientific, Wilmington, DE). 
3.2.5 Cell fractionation 
HepG2 cells were grown at the cell density of 5 X 104 cells/ml on 100 mm dish for 2 
days after transfection. The medium was removed and cells were washed twice with 2 ml ice-
cold PBS. Cells were removed using 1 ml of ice-cold PBS and gentle scraping with cell-scraper, 
and transferred to a pre-chilled eppendorf tube. It was centrifuged at 2000g for 1 min and the 
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supernatant was removed. Cells were resuspended in 125 |il of ice-cold hypotonic buffer (lOmM 
HEPES pH 7.9, 10 mM KC1, 0.1% Triton X-100, and protease inhibitor cocktail (1 tablet to each 
10 ml of the solution), vortexed for 15 sec, and incubated on ice for 15 min with brief mixing in 
between. The lysed cells were then centrifuged at 5000g for 5 min and the supernatant was 
transferred and labeled as cytoplasmic fraction. The pellet was resuspended in 125 pi of ice-cold 
hypotonic buffer and then 125 p.1 of SDS sample buffer (0.25 M Tris pH 6.8, 10% (w/v) SDS, 30% 
(v/v) glycerol, without DTT or dye). This was labeled as nuclear fraction. Another 125 |il of SDS 
sample buffer was added to cytoplasmic fraction and all fractions were boiled for 15-20 min. 
Their protein concentrations were determined using NanoDrop and then stored at -20°C until use. 
3.2.6 SDS-PAGE 
Two 12% polyacrylamide gels were typically made together. The lower gels (resolving 
gels) were made with 3.33 ml of acrylamide/ 0.8% bisacrylamide, 2 ml of 4X lower gel buffer 
(1.5 M Tris-base pH 8.8 and 0.4% (w/v) SDS), 2.67 ml of autoclaved water, and 16 pi of 20% 
(w/v) ammonium persulfate (APS), and 4.8 jxl of TEMED (Sigma) and pouring into a gel 
apparatus (Biorad, Hercules, CA) at about 2/3 full immediately after mixing. About 300 f_il of 
isopropanol was immediately added onto the lower gel to flatten the top surface of the gel. It was 
removed when the gel was solidified. The 5% stacking gel was made with 0.48 ml of 30% 
acrylamide/0.8% bisacrylamide, 0.75 ml of 4X upper gel buffer (0.5 M Tris pH 8.8 and 0.4% 
(w/v) SDS), 1.77 ml of autoclaved water, and 7.5 |il of 20% ammonium persulfate (APS), and 3 
p.1 of TEMED (Sigma) and quickly pouring it on top of the lower gel after mixing and inserting 
the comb. 
Up to 16 pi of each protein sample (50-80 pg) was loaded to each well and 4 pi of 5X 
Sample buffer with 5% (v/v) P-mercaptoethanol and then they were boiled for 5 min. As a 
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reference, 10 jj.1 of pre-stained molecular weight markers (Bio Basic, Inc., Markham, ON) was 
loaded to each gel. Gel was then run in IX SDS running buffer (25mM Tris-base, 200mM 
Glycine, and 1% (w/v) SDS) at 200V for about 1 hour until the bromophenol blue dye reached 
the end of the gel. 
3.2.7 Western blot analysis 
Filter paper and nitrocellulose membrane were cut in equal size as the gel and were 
soaked in IX transfer buffer (25 mM Tris-base, 200 mM Glycine, and 20% (v/v) methanol) for 
20 min. The gel sandwich was assembled on the black side of the gel holder cassette as the 
following: Fiber pad -> filter paper -> gel -> nitrocellulose membrane -> filter paper -> fiber 
pad. It was run at 100V for 1 hour and 30 min in the cold room. 
After protein transfer, the membrane was washed twice with IX PBS (pH 7.4) for 10 min. 
It was incubated with blocking buffer (5% skim milk, IX PBS pH 7.4, and 0.1% Tween-20) for 
1 hour at room temperature or overnight at 4°C. The membrane was washed 3 times with 
washing buffer (0.1% skim milk, IX PBS pH 7.4, and 0.1% Tween-20) for 10 min each and it 
was incubated with 1° antibody (1:3000) for 1 hour at room temp. Another 3 washes were done 
with washing buffer and 2° antibody (1:5000) was added. List of all the antibodies used are 
presented in the Table 8. The blot was washed 3 times again with washing buffer and it was 
developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific 
Inc., Rockford, IL). Blot was imaged with a KODAK Image Station 4000MM PRO (Carestream 
Health INC., Jacksonville, FL). 
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Table 8. List of all the antibodies used for western blot analysis. 
Name of antibody used Company Catalog number Dilution used 
Anti-APEl (mouse) Santa Cruz Biotech Inc. Sc-17774 1:3000 
Anti-Histone HI 
(mouse) Santa Cruz Biotech Inc. Sc-8030 1:3000 
Anti- Cytochrome c 
(mouse) Abeam Ab28137 1:3000 
Anti-Mouse IgG Promega W402B 1:5000 
The blot was stripped for subsequent antibody staining using pre-warmed (55°C) 
stripping solution (62.5 mM Tris pH 6.7, 2% (w/v) SDS, and 100 mM P-mercaptoethanol) for 30 
min. It was washed twice with washing buffer after stripping. 
3.2.8 Immunohistochemistry of breast cancer tissue 
The formalin-fixed and paraffin-embedded (FFPE) breast cancer tissue sections were 
obtained from British Columbia Cancer Agency (BCCA) Tumor Tissue Repository. The slide 
underwent de-paraffinization and rehydration using a series of xylene and graded alcohol as the 
following orders: 1. xylene for 5 min, 2. xylene for 5 min, 3. xylene for 5 min, 4. 100% ethanol 
for 5 min, 5. 100% ethanol for 5min, 6. 95% ethanol for 5 min, and 7. 70% ethanol for 5 min. 
The slides were then washed with IX PBS with shaking 600 rpm for 10 min. Any excess PBS 
was removed by tapping and KimWipe and the tissue sections on the slides were circumscribed 
using an ImmEdge Pen (Vector H-4000, Burlingame, CA). They were blocked with blocking 
buffer for overnight at 4 °C in a humidity chamber. The blocking buffer was removed by tapping 
and primary antibody incubation was done for 1 hour at room temperature in a humidity chamber. 
The dilution for primary antibody was 1:200 in washing buffer. We examined APE1 (Santa Cruz 
Biotech Inc., Santa Cruz, CA) Dcpla (Abeam., Santa Cruz, CA), and TIA-1 (Santa Cruz Biotech 
Inc., Santa Cruz, CA) staining in the breast cancer tissue sections. The slides were rinsed with 
IX PBS using a squeeze bottle and washed three times in IX PBS at room temperature for 10 
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min while shaking at 600 rpm. The secondary antibody was added in 1:1000 dilution in a 
humidity chamber. The slides were again rinsed with IX PBS using a squeeze bottle and washed 
three times in IX PBS at room temperature for 10 min while shaking at 600 rpm. DNA staining 
using POPO™-3 Iodide in 1:1000 dilution was incubated for 20 min in a humidity chamber 
followed by the rinsing and washing steps. 
To mount the sections, one drop of ProLong® Gold antifade reagent (Invitrogen, Eugene, 
OR) was added and a coverslip was gengly applied and was gently pressed to get rid of any 
trapped air bubbles. The edges were sealed with a clear nail polish and it was allowed to set at 
room temperature overnight. For long term storage, the slides were stored at 4 °C in a dark box. 
Each slide was visualized under the confocal microscope following the procedures outlined in 
Chapter 2. 
3.3 Results and Discussion 
3.3.1 WT-APE1-GFP transfected into HeLa and HepG2 cells undergoing cellular stress 
To examine the possible co-localization of APE1 with PBs and/or SGs, we expressed the 
WT-APE1-GFP and the RFP-Dcpla and/or the mRFP-TIA-1 in HeLa (Figure 8) and HepG2 
(Figure 9) cells under oxidative (0.5 mM arsenite) stress or nitrosative (1 mM GSNO) stress. 
In figures 8 and 9, the first column is imaged with flourescence for WT-APE1-GFP 
expressed in both HeLa and HepG2 cells. For both cell types the fluorescence was found to 
localize in the nucleus (Figure 8A, 8D, 9A and 9D). Upon 0.5 mM arsenite (Figures 8B, 8E, 9B, 
and 9D) or 1 mM GSNO (Figures 8C, 8F, 9C, and 9F) treatment, distribution of the WT-APE1-
GFP did not change. We also tested different concentrations of arsenite (0.25 mM, 0.5 mM, 1 
mM and 2 mM) or GSNO (0.5 mM, 1 mM, and 2mM) and different exposure time for arsenite 
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(30 min, 1 hr, 2 hr, and 6 hr) and GSNO (2 hr, 4 hr, and 6 hr). However, we did not observe any 
re-distribution of the WT-APEl-GFP from the nucleus under the various tested conditions (data 
not shown). 
No change in the WT-APEl-GFP distribution upon cellular stress was unexpected 
because previous reports showed that upon treatments with oxidative and nitrosative stressors, 
APE1 was found to localize to the mitochondria or cytoplasm through their immuno-
histochemical and biochemical analyses (Frossi et al. 2002; Qu et al. 2007). This may be 
explained by the fact that the localization of APE1 has not been completely characterized in all 
cell types and there may be variations at least amongst HeLa and HepG2 which were used in our 
experiments and in Raji cells (Frossi et al. 2002) and HEK293 cells (Qu et al. 2007) used by 
others. Varying results from different cell types can also be found in Pines et al. (2005) where an 
oxidative stress caused APE1 translocation into the nucleus in ARO cells. 
The second column represents the RFP-Dcpla (Figure 8A-C and 9A-C) and the mRFP-
TLA-1 (Figure 8D-F and 9D-F) in red color. The RFP-Dcpla was found to localize in the nucleus 
and as dots in the cytoplasm of both HeLa and HepG2 cells with or without 0.5 mM arsenite and 
1 mM GSNO (Figure 8A-C and 9A-C). When the mRFP-TIA-1 was expressed in both HeLa and 
HepG2 cells without any cellular stress (Figure 8D and 9D), they were localized to the nucleus 
generally with one or two dots in the cytoplasm. However, when the cells were exposed to 0.5 
mM arsenite and 1 mM GSNO, there were more dots representing the assembly SGs in the 
cytoplasm (Figure 8E-F and 9E-F). These results are consistent with previous studies on the 
localization of Dcpla and TLA-1 with or without cellular stress (Kedersha et al. 2005; Lin et al. 
2007; Fujimara et al. 2008). 
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The third column represents merged images of the first two columns and the last column 
shows the merged images of the third column with cells under trans-luminescent light (Figures 8 
and 9). There was no overlap of the WT-APE1-GFP and the RFP-Dcpla and/or the mRFP-TIA-1 
in the cytoplasmic dots when we examined the merged images with and without 0.5 mM arsenite 
or 1 mM GSNO (Figures 8 and 9). There were overlaps of the WT-APE1-GFP and the RFP-
Dcpla and/or the mRFP-TIA-1 due to their nuclear expression; however, this nuclear expression 
of the RFP-Dcpla and the mRFP-TIA-1 do not indicate their localization with the PBs or SGs 
respectively (Figures 8A, 8C, 8D, 8E, 9D, and 9E). Therefore, we conclude that there was no 
cytoplasmic co-localization of the WT-APE1-GFP with the RFP-Dcpla and/or the mRFP-TLA-l 
in either HeLa or HepG2 cells (Figures 8 and 9). This suggests that APE1 is at least not likely to 
be involved in mRNA processing that is carried out in PBs and SGs, 
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Figure 8. Expression of WT-APEl-GFP, RFP-Dcpla and/or mRFP-TIA-1 in HeLa cells 
upon treatment with 0.5 mM arsenite and 1 mM GSNO. HeLa cells were plated on 2-
chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 jig of 
plasmid using Lipofectamine reagent. Cells were viewed under confocal microscope two days 
post-transfection. (A-C) Expression of WT-APEl-GFP and RFP-Dcpla. (D-F) Expression of 
WT-APEl-GFP and mRFP-TIA-1. 
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Figure 9. Expression of WT-APEl-GFP, RFP-Dcpla and/or mRFP-TIA-1 in HepG2 cells 
upon treatment with 0.5 mM arsenite and 1 mM GSNO. HepG2 cells were plated on 2-
chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 (ig of 
plasmid using Lipofectamine reagent. Cells were viewed under confocal microscope two days 
post-transfection. (A-C) Expression of WT-APEl-GFP and RFP-Dcpla. (D-F) Expression of 
WT-APEl-GFP and mRFP-TIA-1. 
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3.3.2 APEl population variants transfected into HeLa and HepG2 cells undergoing 
oxidative stress 
As per Chapter 2, there have been no studies on localization of human population 
variants of APEl in cells. In this study, we took the initiative to determine the cellular 
localization of APEl population variants upon oxidative stress (0.5 mM arsenite). The WT-
APE1-GFP did not exhibit any difference in their localization upon 0.5 mM arsenite (Figure 8) 
and 1 mM GSNO (Figure 9) treatments. Under normal condition, we found that single amino 
acid change in APEl did not change the cellular localization of APEl (Figures 4 and 5); 
therefore, we did not expect to see any changes in the cellular localization of APEl population 
variants under 0.5 mM arsenite and 1 mM GSNO treatment. 
When the GFP fusion proteins of I64V, L104R, E126D, D148E, G306A, and D308A 
were transiently expressed in both HeLa and HepG2 cells and exposed to 0.5 mM arsenite, they 
showed nuclear localization (Figure 10) similar to that of observed with the WT-APE1-GFP 
exposed to 0.5 mM arsenite and 1 mM GSNO (Figures 8 and 9). Therefore, we did not perform 
further experiments to look at possible co-localization of APEl population variants with PBs 
and/or SGs. These results re-confirmed that SNPs of APEl population variants do not play any 
role in APEl redistribution with or without cellular stress. 
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Figure 10. Expression of human population variants of APE1-GFP in HeLa and HepG2 
upon treatment with 0.5 mM arsenite. HeLa and HepG2 cells were plated on 2-chamber slide 
at 5X104 cells/ml. After one day in culture, cells were transfected with 1 ng of plasmid using 
Lipofectamine reagent. Cells were viewed under confocal microscope two days post-transfection. 
3.3.3 ND20-GFP transfected into HeLa and HepG2 cells undergoing cellular stress 
To examine the possible co-localization of ND20 with PBs and/or SGs, we expressed the 
ND20-GFP, the RFP-Dcpla and/or the mRFP-TIA-1 in HeLa (Figure 11) and HepG2 (Figure 12) 
cells upon 0.5 mM arsenite and 1 mM GSNO treatments. 
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Figure 11. Expression of ND20-GFP and RFP-Dcpla and/or mRFP-TIA-1 in HeLa cells 
upon treatment with 0.5 mM arsenite and 1 mM GSNO. HeLa cells were plated on 2-
chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 fig of 
plasmid using Lipofectamine reagent. Cells were viewed under confocal microscope two days 
post-transfection. (A-C) Expression of ND20-GFP and RFP-Dcpla. (D-F) Expression of ND20-
GFP and mRFP-TIA-1. 
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Figure 12. Expression of ND20-GFP and RFP-Dcpla and/or mRFP-TIA-1 in HepG2 cells 
upon treatment with 0.5 mM arsenite and 1 mM GSNO. HepG2 cells were plated on 2-
chamber slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 ng of 
plasmid using Lipofectamine reagent. Cells were viewed under confocal microscope two days 
post-transfection. (A-C) Expression of ND20-GFP and RFP-Dcpla. (D-F) Expression of ND20-
GFP and mRFP-TIA-1. 
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In figures 11 and 12, the first column represents expression of the ND20-GFP in green 
color. When the ND20-GFP was expressed in HeLa cells, the fluorescence was found to localize 
to the nucleus and the cytoplasm evenly (Figures 11A and 1 ID). Upon 0.5 mM arsenite and 1 
mM GSNO treatments, distribution of the ND20-GFP did not change in HeLa cells (Figure 11B-
C and 11E-F). Interestingly, when the ND20-GFP was expressed in HepG2 cells, they were 
evenly localized in the nucleus and the cytoplasm without any treatment (Figure 12A and 12D). 
However, they exhibited more nuclear localization with 0.5 mM arsenite (Figure 12B and E) and 
1 mM GSNO (Figure 12C and F) treatments. These phenomena were observed in HepG2 cells 
only and this may be due to the difference of APE1 behaviour in different cells types. We 
therefore decided to further pursue these interesting phenomena as described in sections 3.3.6 to 
3.3.8. 
The second column represents the RFP-Dcpla (Figures 11A-C and 12A-C) and the 
mRFP-TLA-1 (Figures 11D-F and 12D-F) in red color. They exhibited nuclear distribution and as 
dots in the cytoplasm of HeLa (Figure 11) and HepG2 (Figure 12) cells as discussed in section 
3.3.1. The third column represents merged images of the first two columns (Figures 11 and 12), 
and the last column shows the merged images of the third column with cells under trans-
luminescent light (Figures 11 and 12). We found no overlap between the ND20-GFP and RFP-
Dcpla and/or the mRFP-TIA-1 in the cytoplasmic dots in cells treated with or without 0.5 mM 
arsenite and 1 mM GSNO (Figures 11 and 12). Therefore, we conclude there was no co-
localization of the ND20-GFP with the RFP-Dcpla and/or the mRFP-TLA-l in HeLa (Figure 11) 
and HepG2 cells (Figure 12). This suggests that even if APE1 has lost its nuclear localization 
signal and was exposed to cellular stress, there was no co-localization with PBs and/or SGs. 
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3.3.4 N-terminal deleted population variants transfected into HeLa and HepG2 cells 
undergoing oxidative stress 
We next tested the GFP fusion proteins of ND20-population variants including ND20-
L104R, ND20-E126D, ND20-D148E, and ND20-G306A in both HeLa and HepG2 to see if they 
exhibit any different sub-cellular localization when population variants were deliberately 
restricted to the cytoplasm. We found no significant difference in the localization of all ND20-
population variants-GFP as compared to the ND20-GFP in HeLa cells (Figure 13). Interestingly, 
the ND20-population variants-GFP exhibited the same phenomena as that observed for the 
ND20-GFP after arsenite treatment in HepG2 cells: more nuclear localization upon arsenite 
treatment (Figure 13). This was expected because we found that single amino acid change 
outside of 20 amino acids of the N-terminus does not play any role in APE1 localization as 
described in chapter 2. Results from this experiment confirm that the ND20-population variants-
GFP indeed behave the same way as the ND20-GFP upon cellular stress. 
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Figure 13. Expression of human population variants of APE1-GFP in HeLa and HepG2 
upon treatment with 0.5 mM arsenite. HeLa and HepG2 cells were plated on 2-chamber slide 
at 5X104 cells/ml. After one day in culture, cells were transfected with 1 (ig of plasmid using 
Lipofectamine reagent. Cells were viewed under confocal microscope two days post-transfection. 
3.3.5 ND41-GFP transfected into HeLa and HepG2 cells undergoing cellular stress 
It was previously found that a canonical NLS was located in the first seven residues at the 
N-terminus as well as at the amino acid stretch of residues between 8 and 13 (Jackson et al. 
2005). Therefore, we expected to see no co-localization of the ND41-GFP to neither RFP-Dcpla 
nor mRFP-TIA-1 but more to the nucleus in HepG2 cells upon cellular stress like the ND20-GFP. 
In figures 14 and 15, the first column represents expression of the ND41-GFP in green 
color. We expected to see a re-distribution of the ND41-GFP to the nucleus upon cellular stress 
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in HepG2 cells like the ND20-GFP because of their similar distributions under no cellular stress. 
When the ND41-GFP was expressed in HeLa (Figure 14A and D) and HepG2 (Figure 15A and 
D) cells, the fluorescence was found to localize to the nucleus and cytoplasm evenly. However, 
upon 0.5 mM arsenite and 1 mM GSNO treatments, distribution of the ND41-GFP did not 
change in HeLa (Figure 14B-C and E-F) and HepG2 (Figure 15B-C and E-F) cells. Such 
differences may be due to the 21-40 amino acids at the N-terminus involved in APE1 re­
distribution upon cellular stress. To find out why ND20-GFP and ND41-GFP behave differently 
upon cellular stress in HepG2 cells, more experiments were conducted as described in sections 
3.3.6 to 3.3.8. 
The second column represents the RFP-Dcpla (Figures 14A-C and 15A-C) and the 
mRFP-TIA-1 (Figures 14D-F and 15D-F) in red color. They exhibited nuclear distribution and as 
dots in the cytoplasm of HeLa (Figure 14) and HepG2 (Figure 15) cells as discussed in section 
3.3.1 and 3.3.3. The third column represents merged images of the first two columns (Figures 14 
and 15), and the last column shows the merged images of the third column with cells under trans-
luminescent light (Figures 14 and 15). There was no overlap between the ND41-GFP with the 
RFP-Dcpla and/or mRFP-TIA-1 in the cytoplasmic dots with or without 0.5mM arsenite and 
ImM GSNO treatments (Figures 14 and 15). Therefore, we conclude there was no co-
localization of the ND41-GFP with the RFP-Dcpla and/or the mRFP-TLA-l in HeLa (Figure 14) 
and HepG2 cells (Figure 15). 
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Figure 14. Expression of ND41-GFP and RFP-Dcpla and/or mRFP-TIA-1 in HeLa upon 
treatment with 0.5 mM arsenite and 1 mM GSNO. HeLa cells were plated on 2-chamber slide 
at 5X104 cells/ml. After one day in culture, cells were transfected with 1 |ig of plasmid using 
Lipofectamine reagent. Cells were viewed under confocal microscope two days post-transfection. 
(A-C) Expression of ND41-GFP and RFP-Dcpla. (D-F) Expression of ND41-GFP and mRFP-
TIA-1. 
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Figure 15. Expression of ND41-GFP and RFP-Dcpla and/or mRFP-TIA-l in HepG2 upon 
treatment with 0.5 mM arsenite and 1 mM GSNO. HepG2 cells were plated on 2-chamber 
slide at 5X104 cells/ml. After one day in culture, cells were transfected with 1 |ig of plasmid 
using Lipofectamine reagent. Cells were viewed under confocal microscope two days post-
transfection. (A-C) Expression of ND41-GFP and RFP-Dcpla. (D-F) Expression of ND41-GFP 
and mRFP-TIA-l. 
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3.3.6 ND25-GFP, ND30-GFP, and ND35-GFP 
To determine if there are important sequences between amino acids 21 and 40 of APE1 
that may be responsible for the stress response, we generated ND25-GFP, ND30-GFP, and 
ND35-GFP and observed their localization with or without 0.5 mM arsenite treatment in HepG2 
cells. Interestingly, all exhibited even distribution in the nucleus and in the cytoplasm regardless 
of 0.5 mM arsenite treatment (Figure 16). This result suggested that amino acids 21-40 at the N-
terminus of APE1 are responsible for the stress response. This is so because the ND25-GFP, 
which only has 5 extra amino acid deletions after amino acid 20, had lost its stress response in 
comparison to the ND20-GFP. 
A B IC 
Normal 
D |E IF 
0.5 mM 
Arsenite 
30 pm 
Figure 16. Expression of ND25-GFP, ND30-GFP and ND35-GFP in HepG2 cells without 
and with 0.5mM arsenite treatment. HepG2 cells were plate on 2-chamber slide at 5X104 
cells/ml. After one day in culture, cells cells were transfected with 1 (ig of plasmid using 
Lipofectamine reagent. Cells were viewed under confocal microscope two days post-transfection. 
Expression of ND25-GFP (A-B), ND30-GFP (C-D), and ND35-GFP (E-F). 
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3.3.7 Investigation into the possible mechanism for re-distribution of ND20-GFP upon 
cellular stress 
The re-distribution of ND20-APE1 upon cellular stress as described in the section 3.3.3 
(Figure 12) may be due to: 1. nuclear export inhibition of APE1, 2. nuclear import of APE1, 3. 
re-distribution of existing APE1 or newly synthesized APE1, or 4. increased protein degradation 
in the cytoplasm. To test these possibilities, nuclear export inhibitor, nuclear import inhibitor, 
protein synthesis inhibitor and proteasome inhibitor were used (Table 5). 
Without any stress, the ND20-GFP was evenly distributed throughout the nucleus and 
cytoplasm in HepG2 cells. The solvent used for two of the inhibitors, DMSO, did not have any 
effect on their distribution (Figure 17). As expected, both cellular stressors, 0.5 mM arsenite and 
1 mM GSNO, caused the ND20-GFP to be re-distributed into the nucleus (Figure 17). For 
inhibitor studies, we adopted the concentrations and incubation times previously used by others 
as summarized in sections 3.2.1 and 3.2.2. At 5 nM LMB, 50 (iM DQZ, 0.35 mM CHX, 8 (iM 
EPO, and 8 (xM MG-132, no re-distribution of the ND20-GFP was observed (Figure 17). We 
also tested different concentrations of each inhibitors: LMB (5, 10, 20 nM), DQZ (50 and 100 
*iM), CHX (0.175, 0.35, and 0.70 mM), EPO (8 and 16 jiM), MG-132 (8 and 16 |xM) but again 
we did not see any re-distribution of the ND20-GFP (data not shown). 
We next investigated the effect of each inhibitor on the ND20-GFP localization upon 
treatment with 0.5 mM arsenite. Firstly, the protein synthesis was inhibited using 0.35 mM CHX 
and the cells were then exposed to 0.5 mM arsenite. This caused re-distribution of the ND20-
GFP to the nucleus (Figure 17). This suggests that the re-distribution upon cellular stress is not 
due to newly synthesized protein that is re-distributed to the nucleus but is due to the existing 
proteins. Secondly, the nuclear export and import were inhibited using 5 nM LMB and 50 (jM 
DQZ respectively, and the cells were then exposed to 0.5 mM arsenite. This also caused re­
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distribution of the ND20-GFP to the nucleus (Figure 17). Therefore, the results suggest that the 
mechanism is due to neither nuclear export inhibition of the protein from the nucleus nor nuclear 
import of the protein to the nucleus upon cellular stress. Interestingly, when cells were treated 
with the proteasome inhibitors, 8 jaM EPO and 8 |iM MG132, and then 0.5 mM arsenite, the 
ND20-GFP did not show any re-distribution (Figures 17). This suggests that re-distribution of 
ND20-GFP was due to its degradation in the cytoplasm upon arsenite treatment. This observation 
is consistent with previous finding which showed that under stress condition, the ND20-GFP in 
the cytoplasm is discovered to be ubiquitinated and degraded by proteasome (Busso et al. 2009; 
Busso et al. 2011). 
Ubiquitin is a protein that serves as a signal mediator in response to various cellular 
activities where its polymerization triggers the degradation of the ubiquitinated target protein by 
26S proteasome (Char et al. 1989). APE1 is known to be ubiquitinated at the Lys residues 
present in the N-terminus including K24, K25, K27, K31, and K32 (Busso et al. 2009; Fantini et 
al. 2010; Busso et al. 2011). Busso et al. (2009) also discovered that unlike the WT-APE1, 
ubiquitin-APEl were predominantly present in the cytoplasm and might get poly-ubiquitinated 
and degraded in the cytoplasm. Another study observed the increased level of APE1 
ubiquitination upon cellular stress (Busso et al. 2011). These studies agree with what we have 
observed for the ND20-GFP upon cellular stress (Figures 11 and 12) and the ND25-, ND30-, 
ND35-, (Figure 16) and ND41-GFP (Figures 14 and 15). These results suggest that APE1 has a 
region of 21-40 amino acids at its N-terminus where it is responsible for the stress response 
through the ubiquitination pathway. 
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Figure 17. Expression of ND20-GFP in HepG2 cells upon treatment with various cellular 
stressors and inhibitors. HepG2 cells were plate on 2-chamber slide at 5X104 cells/ml. After 
one day in culture, cells were transfected with 1 |ig of plasmid using Lipofectamine reagent. 
After two day of transfection, cells were treated with the following final concentrations of 
inhibitors (6 hr) before viewing under the confocal microscope: 8 jiM MG-132, 8 |*M EPO, 0.35 
mM CHX, 5 nM LMB, and 50 fiM DQZ. Subsequent 4 hr treatments with 0.5 mM arsenite were 
carried to look at the effect of each inhibitor on the ND20-GFP re-distribution. The line in each 
image is used for generating fluorescent intensity graph in figure 19. 
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We obtained the intensity graphs of all the images to quantify our findings. We only 
included the intensity graphs of the HepG2 cells for comparison because we observed change in 
the distribution of ND20-GFP upon cellular stress in HepG2 cells only. 
To confirm that the WT-APE1-GFP was present in the nucleus area with or without 0.5 
mM arsenite or 1 mM GSNO treatments, we chose to show the intensity graphs of figure 9A-C 
as representatives (Figure 18). The fluorescence of the WT-APE1-GFP was mostly present in the 
nucleus area under normal condition (Figure 18A) and under 0.5 mM arsenite and 1 mM GSNO 
treatment (Figure 18B-C). 
Figure 18. Intensity graphs the WT-APE1-GFP in HepG2 cells with or without cellular 
stress. Intensity of green fluorescence from GFP and their scales were obtained from the 
confocal microscope software and cannot be changed. (A) Intensity of the WT-APE1-GFP of 
Figure 9A without cellular stress, (B) Intensity of the WT-APE1-GFP of Figure 9B with 0.5 mM 
arsenite, and (C) Intensity of the WT-APE1-GFP of Figure 9C with 1 mM GSNO respectively. 
The line in each image is used for generating fluorescent intensity graph. 
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We confirmed the distribution of ND20-GFP with or without cellular stress and inhibitors 
in HepG2 cells (Figure 19). We selected to show the intensity graphs of figure 17. Under normal 
conditions, the ND20-GFP was distributed to the cytoplasm and the nucleus (Figure 19A) unlike 
the WT-APE1-GFP showing high intensity peak at the nucleus region (Figure 18A). Upon 0.5 
mM arsenite and 1 mM GSNO treatments, the high intensity peak at the nucleus region was 
observed (Figure 19C-D) which agreed with our findings. There were no changes in the ND20-
GFP intensity distribution under the inhibitors that we used such as 0.35 mM CHX, 5 nM LMB, 
50 (iM DQZ, 8 |iM EPO, and 8 (iM MG-132 (Figure 19E-I). This re-confirmed that the 
inhibitors alone did not have any effects on the distribution of ND20-GFP. The intensity graphs 
of the ND20-GFP treated with either 0.35 mM CHX, 5 nM LMB, or 50 DQZ and then 0.5 
mM arsenite exhibited high intensity peak at the nucleus regions supporting our earlier findings 
(Figure 19J-L). Lastly, evenly distributed intensity graphs of the ND20-GFP treated with either 
the proteasome inhibitors, 8 |aM EPO or 8 jaM MG132, and then 0.5 mM arsenite were observed 
(Figure 19M-N). This also supports our earlier findings that the re-distribution of the ND20-GFP 
may be due to ubiquitination and degradation of the protein in the cytoplasm. 
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Figure 19. Intensity graphs the ND20-GFP in HepG2 cells with or without cellular stress. 
Refer to figure 17 for the lines that were used for obtaining the intensity graph of the ND20-GFP. 
Lastly, to confirm that the ND41-GFP was evenly distributed with or without 0.5 mM 
arsenite or 1 mM GSNO treatments, the intensity graphs of figure 15D-F were used as 
representatives (Figure 20). The fluorescence of the ND41-GFP was evenly distributed under 
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normal condition (Figure 20A) and under 0.5 mM arsenite and 1 mM GSNO treatments (Figure 
20B-C). These supported our earlier finding of the loss of stress response in the ND41-GFP. 
Figure 20. Intensity graphs the ND41-GFP in HepG2 cells with or without cellular stress. 
(A) Intensity of the ND41-APE1 of figure 15D without cellular stress, (B) Intensity of the ND41-
GFP of figure 15E with arsenite, and (C) Intensity of the ND41-GFP of figure 15F with GSNO 
respectively. The line in each image is used for generating fluorescent intensity graph. 
3.3.8 Biochemical analysis of stress response of APE1 in HepG2 cells 
To confirm our live imaging studies on the stress response of APE1 in HepG2 cells, we 
performed biochemical analysis. To do this, we isolated nuclear and cytoplasmic fractions from 
HepG2 cells with or without 0.5 mM arsenite treatment. Histone HI was used as the nuclear 
fraction marker and cytochrome c was used as the cytoplasmic marker (Figure 21 lanes 2, 3, 4, 
and 5). When the WT-APE1-GFP was expressed in HepG2 cells, it showed almost equal amount 
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of the fusion protein in both nuclear and cytoplasmic fractions in normal setting (Figure 21 lane 
1). This was supported by the ratio of 1.012 cytoplasmic/nuclear exogenous APE1 (Figure 22). 
We were able to distinguish exogenous APE1 versus endogenous APE1 using anti-APEl 
antibody because of their size differences of ~60kDa for the GFP-tagged APE1 and ~35kDa for 
the endogenous APE1. The presence of exogenous and endogenous APE1 in the cytoplasmic 
fractions was unexpected because we did not observe any cytoplasmic WT-APE1-GFP with and 
without stress when viewed under confocal microscope (Figures 8 and 9). This discrepancy may 
be due to the presence of dying cells which were not included into microscopy evaluation 
because of their abnormal morphology even though they had WT-APE1-GFP expression. These 
abnormal cells generally produced higher fluorescent signals as compared to normal cells and it 
is now suspected that high expression of the plasmid in these cells eventually led to their change 
in morphology and death. Therefore, these dying cells have likely contributed to the cytoplasmic 
WT-APE1-GFP detected in the western blot analysis because all cells in the 100 mm dish were 
harvested. 
Although the re-distribution of the WT-APE1-GFP to the cytoplasm was not observed 
under confocal microscope, more WT-APE1-GFP was present in the cytoplasmic fraction when 
the cells were treated with arsenite (Figure 21 lane 4). This was supported by the ratio of 1.945 
cytoplamic/nuclear exogenous APE1 (Figure 22). This also agrees with the results reported by 
Qu et al. (2007) in which translocation of APE1 to the cytoplasm upon nitrosative stress in 
HepG2 cells was observed in their western blot analysis. Interestingly, they did not report any 
immunofluorescence study in HepG2 cells. Rather, they reported immunofluorescence 
experiment using HEK293 cells (Qu et al. 2007). This brings up a suspicion that they too might 
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have observed contradicting results as we did for immunofluorescence study and western blot 
analysis in HepG2 cells. 
Both the ND20-GFP and the ND41-GFP exhibited more cytoplasmic localization in 
normal setting with a greater cytoplasmic proportion of the ND41-GFP (Figure 21 lane 1). When 
the stress was added, the ND20-GFP exhibited slight decrease in the cytoplasmic proportion of 
the fusion proteins whereas the ND41-GFP did not show any change (Figure 21 lane 4). These 
were confirmed by the ratios of 1.637 (no stress) and 1.412 (with 0.5 mM arsenite) for the 
cytoplasmic/nuclear ND20-GFP and 2.058 (no stress) and 2.003 (with 0.5 mM arsenite) for the 
cytoplasmic/nuclear ND41-GFP (Figure 22). These results are consistent with previous 
immunofluorescence studies described in sections 3.3.3 and 3.3.5. 
W£APEUjH> ND20-Gn> ND41-Gn> NcHransfetion 
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Figure 21. Western blot analysis of the nuclear and cytoplasmic fractions of HepG2 cells 
with and without arsenite treatment. The concentration of total protein was normalized before 
loading them onto the gel. The blots were stripped and re-probed. The WT-APE1-GFP, the 
ND20-GFP, and the ND41-GFP were detected using anti-APEl mouse antibody. Histone HI 
was used as the nuclear fraction marker. Cytochrome c was used as the cytoplasmic fraction 
marker. 
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Figure 22. Changes in nuclear and cytoplasmic proportions of exogenous APE1 with and 
without arsenite treatment in HepG2 cells. The intensity of each western blot band was 
obtained from three replicates of western blot analyses. Intensity ratio less than 1 means more 
nuclear APE1 than cytoplasmic APE1, Intensity ratio greater than 1 means more cytoplasmic 
APE1 than nuclear APE1, and intensity ratio equal to 1 indicates equal amount of nuclear and 
cytoplasmic APE1 
3.3.9 Localization of APE1 in FFPE breast cancer tissues: A preliminary investigation 
We examined the cytoplasmic expression of APE1 in breast FFPE carcinoma tissues, 
specifically looking for evidence of co-localization of APE1 within PBs and SGs. 
Tissues were stained with APE1 antibody and PoPo-3 which stains DNA. Green color 
represents APE1 staining (Figure 23 first column) and red color represents the DNA staining 
(Figure 23 second column). Merged images of APE1 and DNA staining is shown in the third 
column and the fourth column shows merged images of the third column with tissues under 
trans-luminescent light (Figure 23). Both nuclear (yellow arrows) and cytoplasmic (white arrows) 
expression of APE1 were observed in breast FFPE carcinoma tissues (Figure 23). There were 
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also differences in the expression of APE1 within one section depending on the cell types such as 
breast cells (Figure 23 first row) and duct lining cells (Figure 23 second row). However, with 
very little histology background, it was difficult to distinguish normal breast cells and cells at 
different stages of cancer. Therefore, future immunohistochemistry studies may be required to 
compare normal breast tissue and different stages of breast carcinoma sections. 
Figure 23. Nuclear and cytoplasmic expression of APE1 in breast FFPE carcinoma tissue 
using confocal microscopy. APE1 was stained with alexa fluorphore 488 (AF 488) and the 
nucleus was stained with PoPo-3™-3 Iodide. The nuclear localization of APE1 was highlighted 
by yellow arrows (fat) and white arrows (thin) for the cytoplasmic localization of APE1. 
Studies with APE1 and Dcpla or TIA-1 were carried out in order to look for co-
localizations. First of all, the immuno-stainings of PBs and SGs were not successful (data not 
shown). It may be due to their small sizes and low abundance in cells that make them difficult to 
visualize in tissue sections. Other tissue samples such as prostate or lung carcinomas may show 
different amount of PBs and SGs that we may be able to visualize. Another possibility may be 
the dissociation or destruction of PBs and SGs when the tissues were fixed with formalin 
resulting in an altered protein antigenicity. Formalin fixation has three well-known disadvantages 
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such as slow fixation time, slow quenching of enzymatic activity causing RNA degradation, and 
extensive molecule modification affecting protein antigenicity (Chu et al. 2005). In order to view 
PBs and SGs in the breast carcinoma sections, an antigen retrieval pre-treatment before antibody 
incubation steps may be necessary. We may suggest an alternative fixation technique such as 
ultrasound-facilitated tissue preservation that is found to provide a more rapid and uniform 
molecular preservation (Chu et al. 2005). 
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General Discussion 
4.1 General overview 
The mechanism controlling the mRNA stability or turnover is one of the key points in the 
regulation of gene expression in all eukaryotic species. To date, mRNA surveillance control 
pathways (Section 1.1.1), general 5'-3' and 3'-5' decay pathways (Section 1.1.2), 
endoribonuclease decay pathways (Section 1.1.3), and mRNA locales decay pathways (Section 
1.1.4) have been discovered. APEl is a multifunctional DNA repair protein with a broad range of 
activities including 3' DNA phosphodiesterase, 3'-5' DNA exonuclease, nucleotide incision repair 
(NIR), transcriptional repressor, and RNase H activities (Section 1.2). Its role in RNA 
metabolism has been highlighted recently due to the following key evidence: (i) physical 
association of APEl with other factors that are involved in RNA metabolism (Section 1.3.1), (ii) 
discovery of abasic RNA incision activity of APEl and its role in rRNA control (Section 1.3.2), 
and (iii) discovery of endoribonuclease activity of APEl and its role in the control of mRNA 
abundance (Section 1.3.3). Owing to its multiple roles in cells, APEl has been found to be 
associated with cancers and was targeted as an effort towards developing cancer treatments 
(Section 1.4.1). Interestingly, polymorphism of APEl has been discovered to be associated with 
many diseases including cancers (Section 1.4.2). 
Altered localization of APEl from the nucleus to the cytoplasm has been observed in 
various tumors and has been correlated with more aggressive carcinomas and poor prognoses for 
patients (Section 1.4.3). Although, there is an increasing number of studies that have investigated 
the possible link between the role of APEl and its altered localization, no consensus has been 
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reached. The main goals of this research were (i) to confirm the cellular localization of wild-type 
and N-terminal deletion variants of APEl, (ii) to identify the cellular localization of human 
population variants of APEl, and (iii) to identify the cellular localization of wild-type, N-
terminal deletion, and human population variants of APEl under cellular stress. Overall, we 
found that the N-terminal region of APEl is important for its nuclear localization and that single 
amino acid change outside of this 20-amino acid sequence does not play any role in APEl 
localization. We discovered that APEl is unlikely to be involved in mRNA processing that is 
carried out by the cytoplasmic locales such as PBs and SGs. We have also discovered that the N-
terminal deletion variant of APEl gets degraded in the cytoplasm upon oxidative or nitrosative 
stresses via ubiquitination and degradation by the proteasome. 
4.2 Cellular localization of wild-type, N-terminal deletion variants, and 
human population variants of APEl 
The primary objective of this phase of the investigation was to confirm the presence of a 
NLS of APEl and its role in the localization of APEl in cancer cell lines. In addition, the 
objective was to identify the cellular localization of APEl human population variants. The 
population variants analyzed were I64V, L104R, E126D, D148E, G306A, and D308A. The 
effect of single nucleotide changes of APEl in its localization was also investigated by forcing 
APEl to localize in the cytoplasm through the generation of its N-terminus-deleted population 
variants. 
4.2.1 Roles of N-terminus region of APEl 
The sub-cellular distribution of APEl is found to be predominantly nuclear which is 
consistent with its major abasic DNA incision and redox regulatory activities (Tell et al. 2005). 
Increased expression of APEl has been associated with different tumorigenic processes (Tell et 
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al. 2005). In particular, a higher intracellular expression and cytoplasmic localization of APEl 
have been described in lung, ovarian, thyroid, and breast cancers (Tell et al. 2005), in which they 
correlate with higher tumor aggressiveness and poorer prognoses of the patients (Tell et al. 
2010). Jackson et al. (2005) have identified a canonical nuclear localization signal (NLS) 
residing in the first seven residues at the N-terminus and in the stretch between amino acids 8 
and 13. The N-terminal deletion variants exhibited a cytoplasmic distribution (Jackson et al. 
2005). This highlighted the importance of NLS of APEl in sub-cellular distribution of APEl in 
cells; however, the exact mechanisms regulating APEl distribution are still unknown. The results 
from the expression of WT-APE1-, ND20-, and ND41-GFP in both HeLa and HepG2 cells 
confirmed the role of the NLS in APEl distribution (Sections 2.3.1 and 2.3.2). In these results 
there were almost equal nuclear and cytoplasmic distributions of APEl suggesting that the 
nuclear distribution of ND20- and ND41-GFP in cells was not completely abolished upon loss of 
its NLS (Sections 2.3.1 and 2.3.2). It suggests and supports the existence of more complex 
mechanisms for the cytoplasmic distribution of APEl. 
Another important role of the N-terminus region of APEl has been suggested by previous 
studies. In different cell types APEl was found to localize also in mitochondria where it is 
involved in mtDNA repair activity (Chattopadhyay et al. 2006). This mitochondrial distribution 
of APEl is thought to be due to the proteolytic removal of the first 31-33 amino acids at the N-
terminus, which would promote nuclear exclusion of the protein (Chattopadhyay et al. 2006). 
Recently, the discovery of a mitochondrial targeting sequence within region 289-318, which is 
masked by the N-terminal domain, suggested the need for a specific and regulated unfolding-
refolding of the protein to ensure proper localization (Li et al. 2010). 
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Along with its role in mitochondrial distribution, the N-terminus region of APEl is 
thought to be responsible for modulating stable protein-protein interactions for DNA repair 
(Chattopadhyay et al. 2006). This is supported by the recent work which demonstrated the 
proteolytic removal of the N-terminus region of APEl leading to its functional inactivation in 
vivo without affecting its half-life (Vascotto et al. 2011). The N-terminus region is also thought 
to be involved in the regulation of different APEl functions in an indirect way (Section 1.3). One 
example is APEl's function in activation of transcription factors including p53 and Egr-1 
suggesting APEl is involved in controlling cell cycle arrest and apoptotic programs (Pines et al. 
2005). An additional hypothesis, which is under the evaluation of Dr. Tell's group, is that the 
truncated APEl may play an active role in apoptotic triggering; however, this needs a further 
investigation (Vascotto et al. 2011). In conclusion, N-terminus region of APEl plays a role in 
APEl sub-cellular distribution and protein-protein interaction; however, further work is needed 
to identify the exact and complex mechanism of APEl distribution. 
4.2.2 Roles of single nucleotide polymorphisms (SNPs) of APEl 
Another possible factor influencing changes in APEl distribution is single amino acid 
changes in APEl. A C65S mutation is a very good example and is found to be involved in redox-
assisted folding of APEl in vivo which affects the mitochondrial localization of the protein 
(Vascotto et al. 2011). This is possible because the C65S mutation is found to alter the folding 
process of APEl and controls its interaction with PDIA3 (Vascotto et al. 2011). It is 
hypothesized that C65S may induce conformational change associated with an increased affinity 
toward PDIA3 and this may reduce the fraction of APEl available to translocate into the 
mitochondria (Vascotto et al. 2011). It may also be due to the loss of redox-dependent 
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conformational change required to efficiently respond to oxidative stress causing decreased 
translocation into mitochondria (Vascotto et al. 2011). 
APEl is known to exist as multiple human population variants and researchers have 
found the correlation of APEl polymorphisms with many diseases including cancers (Wilson et 
al. 2011). However, there has been no study in determining the effect of these single amino acid 
changes in APEl on its sub-cellular localization in cells. Interestingly, all of the GFP-tagged 
APEl population variants exhibited nuclear distribution similar to the WT-APE1-GFP (Section 
2.3.2). When they were forced to localize in the cytoplasm the single amino acid changes also 
did not affect the APEl distribution (Section 2.3.2). Therefore, this suggests SNPs in APEl do 
not play any role in APEl sub-cellular distribution, but rather result in functional differences of 
APEl (Kim etal. 2012). 
Of 20 identified human population variants of APEl (Xi et al. 2004; Wilson et al. 2011), 
164V, L104R, E126D, D148E, G306A, and D308A were chosen for our investigation. They were 
chosen because they have been associated with either disease susceptibility, decreased DNA 
incision activity, or decreased RNA cleaving activity. The I64V variation is one example which 
is hypothesized to have no known defect in APEl's functions (Table 9) and decreased lung 
cancer risk (Zienolddiny et al. 2006). The D148E variation is one example which has high allele 
frequency in the human population and is associated with various cancer risks (Section 1.4.2). It 
also has a significantly decreased RNA cleaving activity (Table 9). The G306A variation has no 
identified association with any disease but has a significantly decreased RNA cleaving activity 
with a normal abasic DNA incision activity (Table 9). The L104R, E126D, and D308A have 
both decreased abasic DNA and RNA cleaving activities (Table 9). 
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The L104R and E126D variants were of particular interest because they were found to 
have altered cleavage patterns on c-myc CRD mRNA in vitro as compared to that of WT-APE1 
(Kim et al. 2012). They also were found to be resistant to the effects of a powerful RNase 
inhibitor called RNasin (Kim et al. 2012). There are controversial findings of these two variants 
and their association with Amyotrophic Lateral Sclerosis (ALS) (Olkowski 1998; Hayward et al. 
1999; Tomkins et al. 2000) implicating their role in the formation and progression of ALS. 
Further investigations on APE1 polymorphisms in an effort to discover their effects on protein 
structure, abasic DNA and RNA incision activities, redox regulatory function, and intracellular 
distribution should be carried out in order to gain a better understanding of the correlation of 
APE1 polymorphisms and risks of various diseases. 
Table 9. Summary of DNA and RNA incision activities of human population variants of APE1 
(Kim et al. 2012). 
APE1 
variants 
Activity on abasic 
DNA (%) 
(Hadi et al. 2000; 
Zienolddiny et al. 
2006) 
Activity on abasic 
DNA (%) 
(Kim et al. 2012) 
Activity on CRD 
RNA(%) 
(Kim et al. 2012) 
100 100 100 
I64V N/A N/A N/A 
L104R 56.71 ±26.80 74 60.0 
E126D 60.43 ± 11.16 102 41.4 
D148E 94.36 ±6.20 101 23.3 
G306A 107.22 ±17.13 97 20.4 
D308A 20 ±3.52 71 11.1 
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4.3 Cellular localization of wild-type, N-terminal deletion, and human 
population variants of APEl under cellular stress 
The primary objective of this phase of the investigation was to identify the cellular 
localization of wild-type, N-terminal deletion, and human population variants of APEl under 
cellular stress. Co-localization of APEl with PBs and/or SGs was examined under normal, 
oxidative and nitrosative stress conditions. Differences in APEl distribution upon oxidative and 
nitrosative stresses were also examined along with biochemical analysis. 
4.3.1 Co-localization of APEl with PBs and/or SGs 
In an attempt to find a clue on APE I s role in RNA metabolism, we conducted co-
localization studies of APEl with PBs and/or SGs. mRNA decay is known to be carried out at 
specific sites such as cytoplasmic locales, mitochondria, or ER where mRNAs that need to be 
regulated are concentrated. Examples are IRE la which is an endoribonuclease localized to the 
ER (Han et al. 2009), UPF1 which aids in decapping and deadenylation in PBs (Jin et al. 2009), 
Patlb which is involved in decapping in PBs (Ozgur et al. 2010), and QKI-6 which is a RNA 
binding protein in SGs (Wang et al. 2010). Localization to the specific compartments of a cell 
helps these enzymes to be placed in a substrate-concentrated environment where they can 
function more efficiently. Therefore, we hypothesized that if APEl is localized to PBs and/or 
SGs under normal and/or cellular stress, we could provide further evidence for its role in RNA 
metabolism. The results from the co-localization studies of APEl with PBs and/or SGs indicated 
that APEl is unlikely to be involved in mRNA processing that is carried out in PBs and SGs 
because there was no physical co-localization between these entities (Sections 3.3.1, 3.3.3, and 
3.3.5). This raised two questions: (i) the cytoplasmic APEl and its role in the cytoplasm and (ii) 
other possible locales where APEl is involved in RNA degradation. 
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4.3.1.1 Cvtoplsmic APEl and its proposed roles 
Researchers have considered the role of cytoplasmic APEl mainly as a mtDNA repair 
device in mitochondria upon oxidative stress (Section 1.4.3). Another proposed role of 
cytoplasmic APEl was recently highlighted by the existence of the nucleocytoplasmic shuttling 
of APEl (Zhang et al. 2011). The nucleocytoplasmic shuttling has emerged as an important 
regulatory mechanism for the multifunctional proteins involved in DNA repair pathways and 
maintenance of genomic stability such as BRCA1 and p53 (Zhang et al. 2011). Therefore, they 
propQsed that the nucleocytoplasmic shuttling, spatial and temporal control of APEl may serve 
to regulate the nuclear activity of APEl in cells. 
Other possible cytoplasmic roles of APEl may be identified from the physical association 
of APEl with other proteins in cells. Interaction of APEl with nuclear factor-kappaB (NFKB) 
and subsequent activation of NFKB induced Cox-2 expression has resulted in tumor progression 
and metastasis in vitro and in vivo (Wu et al. 2010). Cytoplasmic APEl caused a poor prognosis 
and a 3.7-fold increased risk of tumor recurrence and/or metastasis; therefore, cytoplasmic APEl 
could enhance lung tumor malignancy (Wu et al. 2010). Overall, this suggests APEl is a redox 
factor that can maintain transcription factors in a reduced state so that the downstream activation 
of cellular mechanisms can occur. 
Physical association of APEl with proteins that are involved in RNA metabolism is well 
studied (Section 1.3.1) and the discovery of RNA incision activity of APEl (Sections 1.3.2 and 
1.3.3) has been recently highlighted. Altogether, this evidence suggests a direct involvement of 
APEl in RNA metabolic pathways. It is still unclear if the role of cytoplasmic APEl is indeed 
maintaining and degrading RNA in cells. Further work such as assesing RNA incision activity of 
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the N-terminus deleted variants of APEl and looking for the difference in RNA level upon 
introduction of cytoplasmic APE 1 in cells are required to confirm such hypothesis. 
4.3.1.2 Possible ways of APEl involvement in RNA metabolism 
APEl can be involved in RNA metabolism either in the nucleus or in the cytoplasm. 
First, since APEl is predominantly present in the nucleus in most cell types, one can assume that 
it plays a role in RNA metabolism in the nucleus. This has been supported by association and 
interaction of APEl to other proteins that are involved in the recognition of damaged RNA, pre-
mRNA maturation or splicing, RNA synthesis, rRNA metabolism, and general ribonucleotide 
metabolism (Secion 1.3.1). Participation of APEl as a RNA cleaving enzyme in the 
aforementioned pathways of RNA metabolism in the nucleus have, however, not been proven 
yet. Second, APEl may play a role in RNA metabolism when it is localized in the cytoplasm. As 
mentioned earlier in this chapter, scientists have proposed that there is nucleocytoplasmic 
shuttling as well as spatial and temporal control of APEl (Zhang et al. 2011). This may serve to 
regulate both the nuclear and the cytoplasmic activities of APEl in cells. For instance, when 
APEl is shuttled to the cytoplasm for a specific reason it may act as an RNA cleaving enzyme, 
whereas it acts as DNA repair enzyme in the nucleus. To carry out its cytoplasmic role, APEl 
may be localized to any cellular compartments in the cytoplasm such as ER or nonspecifically 
throughout the cytoplasm, or associated with polysomes where the RNA cleaving activity of the 
native APEl was first isolated (Barnes et al. 2009). As the nuclear role of APEl in RNA 
metabolism was suggested by its interaction with other proteins that are involved in different 
RNA metabolism pathways, one can suggest its cytoplasmic role by doing the same sets of 
experiments. Therefore, a future experiment should look at protein-protein interaction by APEl 
co-immuno-precipitation and examine its activity when it is associated with polysomes. If one 
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can find a cell line or tissue that is known to have cytoplasmic APE1 predominantly, one can 
carry out a microarray study to see if there are any differences in particular gene expression due 
to the cytoplasmic localization of APE1. 
4.3.2 Stress responsive degradation of N-terminal deletion variant of APE1 
When the cells were treated with both oxidative and nitrosative stresses we did not 
observe any changes in the WT-APE1-GFP and ND41-GFP distributions based on live cell 
imaging (Sections 3.3.1 and 3.3.5). The only change in APE1 distribution upon cellular stress 
was the loss of the cytoplasmic ND20-GFP (Sections 3.3.3, 3.3.7 and 3.3.8). Interestingly, when 
we confirmed our live cell imaging data with the western blot analysis we noted a discrepancy of 
the WT-APE1-GFP distribution. This is discussed in detail in section 3.3.8. The observed 
changes in the ND20-GFP distributions upon cellular stress using western blot analysis are 
consistent with the data from live cell imaging (Section 3.3.8). 
There are four possibilities which could explain the ND20 re-distribution upon cellular 
stress. The first two hypotheses were inhibition of nuclear export of the ND20 and increased 
nuclear import of the ND20 upon cellular stress that resulted in decreased cytoplasmic ND20. 
This suggests that it might have been due to the cell's need of ND20 in the nucleus upon cellular 
stress. The third hypothesis was to confirm whether the re-distribution of the ND20 was due to 
the changes in the existing ND20 or newly synthesized ND20. Using chemical inhibitors, we 
found that none of the above was the cause of the ND20 re-distribution (Section 3.3.7). Lastly, 
we tested the possibility of ND20 degradation upon cellular stress. After treatment with 
proteasome inhibitor to stall all protein degradation in cells, we found that the re-distribution of 
ND20 did not occur upon cellular stress (Seciton 3.3.7). Therefore, we were able to conclude that 
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there is an important 21-40 amino acid region of APEl which is responsible for the APEl 
degradation upon cellular stress. 
This finding is in good agreement with previous studies on critical lysine residues within 
the 21-40 amino acid region of APEl and its effect on APEl functions and localization (Busso et 
al. 2009; Fantini et al. 2010; Busso et al. 2011). There are five critical lysine residues including 
K24, K25, K27, K31, and K32 which are important for APEl interaction with NPM1 upon 
acetylation (Fantini et al. 2010). These residues also serve important roles as ubiquitin acceptor 
sites (Busso et al. 2009). Among these five residues, K24, K25, and K27 are known as the main 
sites for ubiquitination (Busso et al. 2009); however, eliminating K24/25/27 by substituting with 
Arg did not completely abolish APEl ubiquitination, suggesting the supporting role of K31/32 
and C-terminus region of APEl in its ubiquitination (Busso et al. 2011). Depending on cell 
types, cytoplasmic localization of mono-ubiquitinated APEl in the mouse NIH3T3 cell line 
(Busso et al. 2009) and nuclear localization in the HCT116 cell line (Busso et al. 2011) have 
been observed. These mono-ubiquitinated APEl may get poly-ubiquitinated and degraded in the 
cell upon cellular stress (Section 3.3.7). 
These five lysine residues may also play an important role in controlling APEl's 
functional activation of its role in RNA metabolism which is supported by two different findings. 
Researchers have found that ubiquitinated APEl enhanced the global gene suppression as 
demonstrated by an increased DNA affinity of ubiquitin-APEl fusion protein (ub-APEl) (Busso 
et al. 2011). They suggested that ub-APEl may increase its existence on genomic DNA and its 
role as a gene repressor. They also noted many genes involved in stress responses were down-
regulated in the cells expressing ub-APEl as compared to that of the WT-APE1, including 
ferritin and TUBA1 which was confirmed using qPCR assays (Busso et al. 2011). Since it was 
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not reported whether the down-regulation of these genes were due to APEl acting as gene 
repressor by tightly binding to DNA, we can speculate that its down-regulation may be due to the 
activation of RNA incision activity of APEl. This speculation is supported by another finding 
regarding the role of these critical lysine residues. Acetylation of the five critical lysine residues 
were found to inhibit APEl action in RNA metabolism by preventing its RNA-binding activity 
(Fantini et al. 2010). Therefore, we propose that these post-translational modifications of these 
lysine residues may act as a switch for APEl's involvement in RNA metabolism. Upon 
acetylation, these lysine residues may stall APEl's involvement in RNA metabolism. On the 
other hand, ubiquitinated APEl may be an active form for carrying out APEl's role in RNA 
metabolism. Further investigation of ub-APEl activity on RNA incision activity will be needed 
to identify such role of the lysine residues. 
4.4 Immuno-histochemistry of Cancer tissues 
Biomarkers are the molecules that are used as indicators of a biological state. It is a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention (Sahab 
et al. 2011). In cancer, biomarkers have the ability to assess the presence, stage, and malignancy 
of cancerous tissue and they also aid in cancer diagnosis, prognosis, and therapy assessment 
(Sahab et al. 2011). 
There have been many studies looking at APEl distribution or expression in various 
cancers and the complex localizations of APEl in them have been well-reviewed (Evan et al. 
2000; Tell et al. 2005). The nuclear/cytoplasmic and cytoplasmic distributions of APEl are 
found to be correlated with more aggressive carcinomas and poorer prognoses for the patients. 
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This is why APEl has been proposed as a good biomarker for ovarian cancer (Sheng et al. 
2011), cervical cancer (Qung et al. 2009), prostate cancer (Kelley et al. 2001), non-small cell 
lung cancer (Yoo et al. 2008), lip squamous cell carcinoma (Souza et al. 2011), and 
hepatocellular carcinoma (Avellini et al. 2010; Di Maso et al. 2007). There is currently no 
immuno-histochemical data available for APEl in breast, kidney (renal cell), bladder, and 
thyroid cancer tissues. Therefore, to initiate the study, we aimed to examine the cytoplasmic 
expression of APEl in breast FFPE carcinoma tissues specifically looking for any co-localization 
within PBs and SGs (Section 3.3.9). With very little histology background, we encountered some 
difficulties to distinguish normal breast cells from cells at different stages of cancer and 
difficulties staining the tissues with PBs and SGs (Section 3.3.9). Future experiments to improve 
these are suggested in detail in section 3.3.9. 
This initial and preliminary study has provided an analysis of the benign and highly 
differentiated breast cancers from an immunohistochemical perspective. In future, APEl and its 
expression may be used as a prognostic biomarker for aggressive or different stages of breast 
cancers. We suggest to also include the studies of renal cell carcinoma, transitional cell 
carcinoma, and thyroid follicular carcinoma tissues. 
4.5 Concluding remarks 
Several studies have identified the correlation between the cytoplasmic distribution of 
APEl with aggressive tumor progression and poor disease prognoses. Recently, there have been 
a number of studies investigating the role of cytoplasmic APEl but no consensus has been 
reached. The main goals of this thesis were to confirm the cellular localization of wild-type and 
N-terminal deletion variants of APEl and to identify the cellular localization of APEl human 
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population variants. We also investigated the cellular localization of APEl under cellular stress 
and the co-localization of APEl with PBs and/or SGs as an attempt to identify APEl's role in 
RNA metabolism. The role and importance of NLS in APEl sub-cellular distribution was 
confirmed from the results of the expression of WT-APE1-, ND20-, and ND41-GFP in both 
HeLa and HepG2 cells; however, attempts to find out the exact mechanisms regulating APEl 
distribution were not achieved in this thesis. A lack of changes in the distribution of APEl 
human population variants implies that the SNPs of APEl do not play any role in the sub-cellular 
distribution of APEl. This thesis is the first study to report the localization of APEl human 
population variants. The discrepancy in the ND20 distribution upon cellular stress from the live 
cell imaging and western blot analysis was due to the loss of the cytoplasmic ND20-GFP through 
ubiquitination and degradation. This highlights the important five lysine residues that are 
responsible for ubiquitination and APEl degradation upon cellular stress. These five lysine 
residues may also play an important role in modulating the activation APEl in its role in RNA 
metabolism. Future studies on ub-APEl RNA incision activity are expected to provide more 
insight into the role of lysine residues and their modification in APEl function. Lastly, the initial 
and preliminary APEl immuno-histchemical analysis of the FFPE breast cancer tissue provide 
the first insight into APEl distribution in breast cancer. Future studies should include 
comparison of normal breast tissue and different stages of breast cancer tissues, and other cancer 
tissues that have not been examined. This is expected to provide extensive analyses of the 
cancers from an immuno-histochemical perspective and insight into the adequacy of using APEl 
as a prognostic biomarker for aggressiveness or staging of cancers. 
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